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A Résumé (français) 
Mon projet de thèse s’inscrit dans le cadre de l’immunothérapie du cancer qui consiste en 
différents traitements visant à optimiser la réponse immunitaire du patient contre ses cellules 
cancéreuses.  
Mon travail de thèse s’articule autour de trois projets liés à l’immunothérapie anti-cancer. 
Dans le premier projet, mon intérêt s’est porté sur la manipulation contre les tumeurs des 
lymphocytes invariant Natural Killer T cells (iNKT). En l’occurrence, j’ai étudié les mécanismes 
responsables de l’induction de l’anergie des cellules iNKT suite à une première stimulation par 
le ligand a-galactosylceramide, qui limite grandement l’efficacité de ces cellules. Notre étude 
comparative d’analogues de l’αGalCer a démontré que les glycolipides de structure chimique 
plus soluble connus pour induire une réponse de type Th2, provoquaient beaucoup moins 
d’anergie que les ligands de type Th1 plus hydrophobes. En outre, nous avons montré que 
n’importe quelle cellule présentatrice d’antigènes exprimant le CD1d est capable d’induire 
l’anergie des cellules iNKTs lorsque chargée avec un ligand « Th1 », et que la présentation des 
glycolipides dans les domaines « lipid rafts » particulièrement présents dans les cellules 
dendritiques (DCs) ne semble pas être un prérequis pour l’induction de l’anergie des 
lymphocytes iNKTs. Notre hypothèse est que l’induction de l’anergie par différents analogues 
de l’αGalCer résulte de l’interaction du ligand avec le récepteur de cellules T (TCR) iNKT. Dans 
le second projet, j’ai investigué comment améliorer l’effet adjuvant des cellules iNKT sur la 
réponse antitumorale des lymphocytes T CD8. Dans ce cadre, j’ai choisi un analogue αGalCer 
de type Th1, qui confère aux cellules iNKT de meilleures propriétés transactivatrices sur la 
maturation des DCs. J’ai pu confirmer l’efficacité des DCs chargées avec l’αGalCer en tant que 
vaccin anticancer. De plus j’ai démontré de manière innovante une importante amélioration 
de l’effet antitumoral en ajoutant à la vaccination αGalCer/DCs, un traitement anti-
Programmed cell death protein 1 (PD1), connu pour restaurer la fonctionnalité des 
lymphocytes T dans les tumeurs. Mes résultats montrent aussi que l’importance de l’effet 
additif entre ces deux traitements dépend de l’immunogénicité du modèle tumoral.  
Finalement, mon troisième projet investigue la fonctionnalité in vivo du TCR endogène des 
lymphocytes T CD8 lorsque transduits avec un récepteur d’antigène chimérique (CAR). Nous 
avons constaté que lorsque ces lymphocytes T co-expriment un CAR et que leur TCR est activé 
par une infection bactérienne (Listeria-OVA) ou virale (LCMV), ces cellules meurent par 
apoptose 7 jours après l’infection. Nous avons découvert que ces lymphocytes, mais pas les 
cellules contrôles, expriment de hauts niveaux de Fas et FasL et meurent généralement entre 
les jours 6 et 7 post-infection.  L’apoptose massive des cellules CAR lorsque activées par leur 
TCR ne peut pas être évitée par le blocage de Fas, suggérant qu’il existe des mécanismes 
parallèles à Fas induisant leur apoptose. L’ensemble de mes résultats a amélioré la 
compréhension des lymphocytes iNKT et de leur potentiel en immunotherapie du cancer, et 
a révélé un mécanisme très important pour l’optimisation de l’immunothérapie utilisant des 
CAR.   
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B Summary (english) 
My PhD project has been conducted in the context of cancer immunotherapy which aims to 
manipulate the immune system of the cancer patient against his tumor.  
More specifically, my thesis work has focused on three projects related to cancer 
immunotherapy. In the first project, I have studied the mechanisms underlying the onset of 
anergy in invariant Natural Killer T lymphocytes (iNKT) after a single injection of the CD1d 
ligand α-galactosylceramide (αGalCer). Our comparative study of various analogs of αGalCer 
has shown that rather polar ligands known to generate a Th2 type of iNKT cell response were 
also inducing less anergy than the apolar Th1 type αGalCer ligands. We also observed that all 
antigen presenting cells (APCs) induced similar levels of iNKT cell anergy when loaded with 
Th1 glycosphingolipids (GSLs). Finally, we observed that enriched GSL presentation within lipid 
raft domains of APCs, which is a hallmark of Th1 GSLs, is likely not required to induce iNKT cell 
anergy. Our hypothesis is that the induction of iNKT cell anergy might rather depend on the 
iNKT T cell receptor (TCR) recognition of the glycolipid. 
My second project aimed at improving the adjuvant activity of the iNKT cell agonist glycolipid 
αGalCer, when formulated as a dendritic cell (DC) vaccine against cancer. In this concept, I 
chose a Th1-type αGalCer analog, as we demonstrated their superior capacity to induce the 
transactivation of DCs by iNKT cells. I could confirm the efficacy of αGalCer-loaded DCs to 
generate an antitumor CD8 T cell response. Importantly, I revealed the superior antitumor 
activity of the combined iNKT/DC vaccine with Programmed cell death protein 1 (PD1) 
blockade, known to restore the functionality of intratumoral T cells, as compared to the 
treatments alone.  My results also showed that the combined antitumor activity between 
DC/αGalCer vaccine and anti-PD1 depended on the immunogenicity of the tumor model. 
Finally, my last project investigated the functionality of the resident TCR in CD8 T cells 
transduced with a chimeric antigen receptor (CAR). We observed that CAR CD8 T cells undergo 
massive apoptosis in vivo when activated via their TCR in the context of a bacterial or viral 
infection. Furthermore, CAR T cells, but not mock-transduced T cells, express high levels of Fas 
and FasL from day 6 post infection. Finally, the in vivo CAR T cell deletion upon TCR stimulation 
could not be rescued by the blockade of Fas signalling, suggesting that parallel signalling 
pathways contribute to the apoptosis of TCR-engaged CAR T cells. Altogether, my results have 
improved the comprehension of iNKT cells and in particular their potential for therapeutic 
cancer vaccines. Moreover, the results of the third project have revealed an important 
mechanism in CAR T cell therapy, which may allow new improvements for its application to 
solid tumors.   
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C Résumé Large Public (français) 
De nombreuses études ont démontré l’énorme potentiel thérapeutique des approches 
d’immunothérapie du cancer. Celles-ci se fondent sur des méthodes visant à améliorer la 
réponse immunitaire du patient contre sa tumeur. Toutefois, des progrès dans la 
compréhension du système immunitaire et de son interaction avec les tumeurs sont 
nécessaires afin d’utiliser au mieux ces nouvelles thérapies. Ce projet de thèse traite de trois 
problématiques relatives à l’immunothérapie. La première étudie les lymphocytes invariant 
Natural Killer T (iNKT) qui représente une intéressante cible immunothérapeutique car, une 
fois activées par le glycolipide αGalactosylCeramide (αGalCer), ces cellules activent la 
maturation des cellules dendritiques, qui sont très importantes pour l’initiation d’une réponse 
immunitaire adaptative. Malheureusement, après une première activation, les lymphocytes 
iNKT deviennent anergiques, ce qui signifie qu’ils ne peuvent plus répondre à des stimulations 
ultérieures. Nous avons découvert que l’anergie induite par le glycolipide αGalCer ne dépend 
pas de la nature de la cellule qui le présente aux lymphocytes iNKT, ni de la durée de cette 
interaction, ni du domaine membranaire dans lequel il est présenté. Notre hypothèse basée 
sur nos résultats est qu’elle dépend de facteurs intrinsèques aux glycolipides utilisés. Dans le 
second projet, nous démontrons que la vaccination de souris avec des cellules dendritiques 
chargées avec le glycolipide αGalCer combiné à un antigène tumoral est très efficace dans 
l’induction d’une réponse immunitaire dirigée contre la tumeur médiée par les lymphocytes 
T CD8. De plus, nous montrons que ce vaccin peut être amélioré par l’ajout d’un traitement 
anti-Programmed cell death protein 1 (PD1) connu pour restaurer la fonctionnalité des 
lymphocytes T à la tumeur. Finalement, dans le troisième projet, nous étudions la 
fonctionnalité du récepteur endogène des lymphocytes T transduits pour exprimer un CAR, 
qui est un récepteur antitumoral artificiel de haute affinité. Cette approche a montré des 
effets cliniques spectaculaires dans le traitement de leucémies. Dans ce projet, nous 
démontrons que l’activation des lymphocytes T CD8 via leur CAR ne pose aucun problème in 
vivo, mais que leur activation via leur récepteur TCR endogène induit le suicide de ces cellules, 
qui reçoivent un signal de mort. La voie de signalisation d’apoptose Fas/FasL semble impliquée 
mais pas suffisante, car son blocage ne permet que partiellement la survie des cellules. 
Finalement, ces résultats expliquent pourquoi les essais d’activation combinées TCR et CAR 
ont échoué et sont donc de première importance pour les développements futurs de 
thérapies utilisant les CARs pour le traitement de tumeurs solides. 
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E Abbreviations 
ACT Adptive cell transfer 
ADCC Antibody-dependent cell-mediated cytotoxicity 
AICD Activation-induced cell death 
αGalCer  -GalactosylCeramide 
 β2m  β2-microglobulin 
CAR Chimeric antigen receptor 
CTLA-4 Cytotoxic T lymphocyte-associated molecule-4 
DAG Diacyl glycerol 
DAMPs Damage-associated molecular patterns 
DC Dendritic cell 
EDTA Ethylenediaminetetraacetic acid 
FCS Fetal calf serum 
GSL Glycosphingolipid 
HER2 Human Epidermal Growth Factor Receptor-2 
Hexb β-hexosaminidase 
iGb3 Isoglobotrihexosylceramide 
IL-2/7/15 Interleukin-2/7/15 
IL7R α  IL7 receptor subunit α 
IDO Indoleamine 2,3-dioxygenase 
IP3 Inositol 1,4,5-trisphosphate 
ITAM Immunoreceptor tyrosine-based activation motif 
KLRG1 Killer cell lectin-like receptor subfamily G member 1 
MDSC Myeloid-derived suppressor cell 
MPL Monophosphoryl lipid A 
mTORC1 Mechanistic target of rapamycin complex 1 
NK Natural Killer 
NSCLC Non-small-cell lung cancer 
PIP2 phosphatidylinositol 4,5-bisphosphate  
PD1 Programmed cell death 1 
PKC θ Protein Kinase C θ 
PTEN Phosphatase and tensin homolog 
RasGRP RAS guanyl nucleotide- releasing protein 
ROR γ  RAR-related orphan receptor gamma 
SHP-2 SH2-domain containing tyrosine phosphatase 2 
TAA Tumor-associated antigen 
TAM Tumor-associated macrophage 
TCR T-cell receptor 
TILs Tumor-associated lymphocytes 
TLR Toll-like receptor 
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G Introduction 
G.1 Invariant Natural Killer T cells  
Invariant Natural Killer T cells or iNKT cells belong to the family of innate-like T cells, such as 
γ∂ T cells and MAIT. iNKT cells recognize lipid antigens presented on CD1d and express a semi-
invariant T cell receptor: the invariant Vα14Jα18 chain in mouse or Vα24Jα18 in human  
combined with Vβ2/7/8.2 in mouse and Vβ11 in human1. They usually co-express NK-specific 
receptor such as NK1.1 or DX5 in mice and NK1.1 or CD56 in humans2,3, and were identified 
by their recognition of the marine sponge-derived glycosphingolipid (GSL) α-
GalactosylCeramide (αGalCer) in the context of CD1d3,4. 
 CD4 T cells CD8 T cells iNKT cells 
Antigen 
recognition 
peptides on MHC II peptides on MHC I lipids on CD1d 
Co-receptor 
expression 
CD4 CD8 DN or CD4 in mice 
DN, CD4 or CD8 in humans 
Localization Lymphoid organs Lymphoid organs Lymphoid organs and liver 
Frequency 35% in spleen 40% in spleen 2.5% of T cells in the spleen 
and 30% in the liver3 
Subsets Th1, Th2, Th17 or 
Treg 
Cytotoxic T lymphocytes NKT1, NKT2, NKT17, 
NKT105–8 
Table 1 - Comparative description of iNKT cells and conventional T lymphocytes. 
 
G.1.1 Antigen recognition 
The iNKT TCR recognize lipid antigens presented on CD1d, which is structurally very similar to 
MHC I9. iNKT cells were identified because of their reactivity to the prototypic  agonist 
αGalCer, which has the optimal binding capacity to CD1d10 and was originally discovered 
because of its antitumor properties11. It consists of an acyl and a sphingosine chain of 26 and 
15 carbons respectively, bound to a galactose sugar ring by an α glycosidic bond, which is not 
present in mammals. 
 12 
 
Figure 1 - a: the crystal structure of human CD1d bound to αGalCer from the side and from the top. b: 
the chemical structure of αGalCer. Adapted from 10. 
Like for MHC I molecules, the α1 and α2 domains of CD1d form the antigen binding site, while 
the α3 domain is responsible for the interaction with β2-microglobulin (β2m)12,13 (Figure 1). 
However, instead of the peptide binding groove present in MHC I and II molecules, the CD1d 
molecule is characterized by a two deep pockets named A’ and F’ in mouse and A’ and C’ in 
human, which are very hydrophobic12 and interact with the lipid chains of the GSL10,13. For 
instance, a study of the crystal structure of human CD1d loaded with αGalCer showed that the 
acyl chain of the glycosphingolipid is buried in the A’ pocket and the sphingosine chain in the 
C’ cavity, while the galactose ring protrudes outside of the binding pocket and is exposed to 
the TCR10. Indeed, the combined crystal structure of the human iNKT TCR bound to 
CD1d/αGalCer pointed out that the TCR invariant α chain plays the major role in the 
interaction with CD1d/αGalCer with the CDR1 domain interacting only with αGalCer, and the 
CDR3  loop recognizing both CD1d and αGalCer14, while Indeed, the CDR2 and 3 domains of 
the β chain interact exclusively with CD1d.   
Co-incubation experiments of DCs, iNKT cells and heat-killed bacteria showed that some 
bacteria species such as Ehrlichia muris and Sphingomonas capsulata could induce iNKT cell 
activation even when DCs were deficient for the Toll-like receptor (TLR) signalling components 
MyD88 and Trif, while others such as Salmonella typhimurium required functional MyD88 and 
Trif signalling in DCs to properly activate iNKT cells. However, in all cases, CD1d expression on 
DCs was always required for iNKT cell activation15, and DCs deficient in the β-hexosaminidase 
(hexb) enzyme required for the synthesis of the self-derived glycolipid iGb316, were not able 
to stimulate iNKT cells when co-incubated with Salmonella bacteria15. Along the same line, a 
study combining in vitro and in vivo data showed that activation of iNKT cells by DCs upon 
Salmonella typhimurium infection depended on both the presentation of endogenous 
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glycolipids and IL-12 secretion by DCs17. Furthermore, blockade of iGb3 recognition with a 
lectin precluded the activation of iNKT cells by DCs when the cells were cocultured with 
Salmonella, but not Ehrlichia or Sphingomonas species15,16. Collectively, these observations 
demonstrate that iNKT cell activation by bacterial components can occur either via the direct 
recognition of bacterial glycolipids presented by CD1d-expressing DCs, or indirectly via IL-12 
released by TLR- activated DCs combined with the CD1d presentation of the self-GSL iGb3. The 
two models of iNKT activation are illustrated on Figure 2.  
 
Figure 2 - The two models of iNKT cell activation. iNKT cells can be activated by the direct presentation 
of bacteria-derived lipids or by self-lipids and cytokines. Adapted from 18. 
G.1.2 Ligands presented to iNKT cells: self, microbial or artificial 
Most glycolipids presented on CD1d to iNKT cells are glycosphingolipids (GSLs), which have an 
α anomeric bond between the sugar head and the sphingolipid tail, such as αGalCer and α-
galacturonosyl ceramide, which is found in Sphingomonas bacteria19. Another class of CD1d 
ligands are glycerolipids, such as diacylglycerolipids found in the pathogenic bacteria Borrelia 
burgdorferi20,21. 
Mammalians are not able to synthesize glycolipids with an α anomeric bond22, but self-derived 
glycolipids with a b-anomeric bond have been shown to bind to CD1d and activate iNKT cells. 
A well characterized example is isoglobotrihexosylceramide (iGb3). It is present in the mouse 
thymus23 and was proposed to play a role in the positive selection of iNKT cells24. The reason 
why molecules with different structures, such as pathogen-derived α-linked glycolipids and 
self-derived β-linked lipids, can be recognized by the iNKT TCR came from the resolution of 
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the crystal structure of CD1d/iGb3/TCR. Indeed, it revealed that the interaction with the TCR 
modifies the orientation of the β-linked sugar moiety towards an orientation that resembles 
that of α-linked lipids25, explaining how a single TCR can recognize structurally different 
antigens. 
G.1.3 The crosstalk of iNKT cells with innate and adaptive immunity 
iNKT cells play pleiotropic roles in the immune system by interacting with multiple immune 
cells, of both myeloid and lymphoid lineages. 
First, the crosstalk of iNKT cells with DCs has been extensively described. Indeed, DC 
presentation of αGalCer/CD1d to iNKT cells combined with CD40-CD40L interaction induces 
the production of IL-12 by DCs and the upregulation of the IL-12 receptor, with a concomitant 
up-regulation of CD40L and increased IFNγ secretion by iNKT cells26. Hence blockade of IL-12 
or CD40 results in a strong decrease of iNKT cell activation27. 
Importantly, the crosstalk between iNKT cells and DCs, results in a fast and potent 
transactivation of NK cells via both the IL-12 secreted by DCs and the massive production of  
IFNγ by activated iNKT cells28.  
iNKT cells also interact with B cells. A study has shown that coculture of iNKT cells and B cells 
enhances the maturation of the B cells and also immunoglobulin production29. Another study 
showed that vaccination with αGalCer increases the antibody response, and this effect is 
mediated by CD40L presentation on iNKT cells to B cells. Furthermore iNKT cells support the 
homeostatic maintenance of memory B cells29. 
Finally, iNKT cells also influence the function of macrophage. In a model of Borrelia burgdorferi 
infection in mice, the IFNγ secretion by activated iNKT cell upon recognition of bacteria-
derived lipid antigens30, directly enhanced the phagocytic activity of macrophages and also 
increased their CD1d expression, suggesting a positive feedback loop between macrophages 
and iNKT cells. In contrast, resident iNKT cells in adipose tissue rather exhibit an anti-
inflammatory M2 macrophage polarization and prevent macrophage-induced inflammation 
through IL-10 production31,32. Overall, the outcome of iNKT cell activation is context-
dependent, whether in pathogenic or homeostatic conditions. 
G.1.4 The development of iNKT cells 
iNKT cells differentiate from T cell progenitors and their specific fate is determined at the 
double-positive (DP) stage, when immature thymocytes express both CD4 and CD8 and 
rearrange their T cell-receptor33. The key signal in acquiring the iNKT cell identity is the 
 15 
presentation of self-glycolipids by other DP thymocytes, which will select for the mature semi-
invariant TCR34. Immature T cells expressing the iNKT TCR will undergo a specific 
differentiation program, starting at the stage 0, characterized with the expression of the 
surface markers CD4, CD69 and CD24. Then, stage 1 is defined by the downregulation of CD24. 
Afterwards, stage 2 cells upregulate CD44, a marker of effector lymphocytes. Finally, stage 3 
is associated with the acquisition of NK-associated markers. Differentiation to stage 3 occurs 
both in the thymus and in the periphery33 (Figure 3). A key transcription factor involved in the 
constitutive effector functions of iNKT cells is PLZF and its ablation impairs iNKT cell thymic 
expansion35. PLZF is highly expressed in stages 1 and 2 of iNKT cell maturation and its 
expression decreases at stage 3. Interestingly, PLZF-deficient iNKT cells show a phenotype 
comparable to naïve T cells, characterized by a deficient secretion of effector cytokines and 
by the expression of CD62L which relocate them to lymph nodes35. The induction of PLZF 
expression is directly induced by Egr2, which results from the strong TCR signalling in early 
iNKT cell precursors33. The high TCR signalling in iNKT cell precursors does not induce their cell 
death them by negative selection, as it does during thymic development of CD4 and CD8 T 
cells. Their survival likely result by their selection mediated by DP thymocytes, which do not 
express CD80 or CD86 in contrast to thymic stromal cells, responsible for the thymic selection 
of CD4 and CD8 T cells36,37. Instead iNKT precursors receive a signal through Slamf1 (CD150) 
and Slamf6 (Ly108), which is necessary for their development38. In addition to Slam molecules, 
several pathways are selectively required for iNKT cell development, but not for conventional 
T cells, such as c-Myc39 or mTORC140. 
Finally, RORγt plays also a central role in iNKT cell development. Indeed, this transcription 
factor increases the lifespan of thymocytes undergoing TCR rearrangement. Its ablation 
prevents thymocytes from rearranging the Vα14 and the Jα18 gene fragments together41. 
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Figure 3 - iNKT cell development and maturation occurs through distinct stages, which can be identified 
with the expression of specific surface markers. Adapted from 42. 
G.1.5 iNKT cell subsets 
Like CD4 T cells, iNKT cells are subdivided into different functional subsets, characterized by 
defined cytokine profile and expression of transcription factors. In mice, NKT1 cells express 
the transcription factor T-bet, often express NK1.1 and CD122 and secrete IFNγ. They can be 
CD4+ or CD4-. iNKT2 cells express CD4 and IL-17RB and produce typical Type-2 cytokines such 
as IL-4 and IL-1318. iNKT17 cells do not express CD4 or NK1.1 and secrete IL-17A5. Finally, a 
regulatory subset of iNKT cells has been identified and named NKT10. These NKT10 express 
surface molecules similar to regulatory CD4 T cells, but do not express their master 
transcription factor FoxP3. They exert a regulatory function through IL-10 secretion6. 
Unlike mouse iNKT cells, their human homologs can express CD8. CD8+ and CD4-CD8- have the 
highest expression of NK-related receptors such as CD56 and NK1.1. They also secrete more 
Type-1 cytokines than their CD4+ counterparts. Alternatively, CD4+ iNKT cells are more potent 
to secrete Type-2 cytokines than the other subsets43. 
G.1.6 αGalCer analogs differentially polarize iNKT cells  
 Several derivatives of αGalCer have been synthesized and characterized by their ability to 
induce preferentially a Th0, Th1 or Th2 response in murine iNKT cells, which has been defined 
by the ratio between the serum levels of IFNγ at 18h and IL-4 at 2h post injection, and also by 
their ability to transactivate NK cells. The mechanisms underlying the differential capability of 
such antigens to bias the polarization of iNKT cell are still debated. The group of Steven Porcelli 
has shown that Th2-biasing αGalCer analogs are more polar than their Th1 counterparts and 
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can load on CD1d directly at the cell surface of APCs, while the more hydrophobic Th1 GSLs 
are internalized and require endosomal lipid transfer factors mainly of the saposin family to 
be loaded on CD1d (Figure 4). As a result, Th2 GSLs result in a fast and transient iNKT cell 
activation with a peak of IFNγ at 6h, while Th1 GSLs lead to a delayed iNKT cell response with 
the peak of IFNg at 18h post injection. In addition, CD1d loaded with Th1-biasing GSLs were 
shown to be preferentially localized within lipid rafts44, while Th2-biasing GSLs were excluded 
from these cholesterol-rich membrane micro-domains, and were quickly detached from CD1d 
upon endosomal trafficking45. However, upon neutralization of endosomal acidification, 
increased localization of Th2 GSLs in lipid rafts was obtained which resulted from their 
stabilized CD1d presentation and thus allowed them to acquire Th1 properties46. These results 
clearly suggest that the site of CD1d loading and presentation likely explains the properties of 
various αGalCer analogs.  
 
Figure 4 - Th1 glycolipids require endocytosis and are loaded on CD1d in acidic endosomes, while their 
Th2 counterparts are surface-loaded but rapidly unloaded upon CD1d recycling through endosomes. 
Th1 or Th2 αGalCer analogs also exhibit different affinities for APCs, as Th1 GSLs load 
preferentially on DCs, which are rich in lipid rafts. Another study by Bendelac et al postulated 
that Th1 GSLs were mainly presented by DCs in vivo and Th2 GSLs by non-professional APCs, 
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such as B cells, explaining the different ability of these molecules to bias the cytokine response 
of iNKT cells47. This hypothesis was however challenged by a study from Porcelli et al. 
demonstrating that CD8α DCs are the main APCs responsible for both Th1 and Th2 GSLs 
presentation in vivo48, which could also result from their highest CD1d expression, as 
compared to B cells or macrophages.  
G.1.7 iNKT cell anergy 
The injection of αGalCer in mice strongly activates iNKT cells resulting in cytokine secretion 
and cell proliferation. However, iNKT cells rapidly downregulate their TCR or die by apoptosis 
and within one week, their frequency is back to steady state. Interestingly, after this initial 
antigen stimulation, iNKT cells become unresponsive to a second challenge with αGalCer, as 
they fail to proliferate, secrete cytokines and transactivate other cells such as NK cells49. This 
phenomenon is referred as iNKT cell anergy or hyporesponsiveness. The mechanisms 
underlying iNKT cell anergy are still poorly understood. However, some molecular players 
have been identified. Indeed, blockade of PD1 during the priming with αGalCer partially 
prevents the induction of iNKT hyporesponsiveness. However, iNKT cell anergy cannot be 
reverted by PD1 blockade once it has been induced50. Later, it was hypothesized that TCR 
signalling with CD28 costimulation is more potent at rendering iNKT cells anergic than TCR 
signalling alone and thus DCs loaded with αGalCer are better iNKT cell anergy inducers than B 
cells51. Another study showed that Cbl-b-deficient iNKT cells are resistant to anergy since cbl-
b was shown to promote the degradation of CARMA-1, an key molecule of the NF- κB 
pathway52. Finally, the deficiency of TSC1, a negative regulator of mTORC1 renders iNKT cells 
resistant to anergy induction. Indeed these cells failed to upregulated PD-1, Egr2 and Grail, 
which are negative regulators of T cell activation53.  
Interestingly, one recent study has shown that Th2-biasing αGalCer derivatives induce less 
iNKT cell anergy than their Th1-biasing counterparts54, suggesting that the kinetic of iNKT cell 
activation might directly influence the responsiveness of iNKT cell to re-challenge. In support 
of this hypothesis, studies in our group have shown that CD1d-antitumor fusion proteins lead 
to potent but transient iNKT cell activation, which maintained them reactive to multiple 
antigen restimulation, similarly to Th2 αGalCer analogs55,56.   Finally, one recent study revealed 
that instead of becoming anergic, iNKT cells may rather change their cytokine profile upon 
antigen stimulation, and differentiate into a regulatory phenotype resembling that of 
regulatory T cells57. 
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G.1.8 Lipid antigen presentation by CD1d 
CD1d expression is restricted to thymocytes and APCs, such as DCs, B cells and macrophages3.  
Molecules of the CD1 family are folded and assembled with β2m in the endoplasmic reticulum, 
helped by the chaperones calnexin and calreticulin58,59. After folding, CD1d molecules traffic 
to both the cell membrane and late endosomes60. However, most CD1d molecules go first to 
the cell membrane and are then rapidly re-internalized and targeted to endosomes before 
going back to the membrane61. The endosomal loading of lipid antigens on CD1d depends 
mainly on the lipid transfer saposin B62. On the cell surface, association with the adaptor 
proteins AP2 and AP3 is required for the targeting of CD1d from the membrane to late 
endosomes63,64. 
G.1.9 The adjuvant effect of iNKT cells on adaptive immunity 
The interaction between iNKT cells and DCs results in the increased maturation of DCs. Thus, 
presentation of αGalCer to iNKT cells and T cell peptide antigens by the same DC drastically 
increases the T cell response65,66, as DC maturation is a key step for the initiation of T cell 
immunity.  
This occurs through a well-described mechanism in which the recognition of glycolipids loaded 
on CD1d on DCs by iNKT cells triggers their secretion of IFNγ, which favours the production of 
IL-12 by DCs67. The presentation of CD40L by iNKT cells to DCs enhance the maturation of the 
latter. This process occurs through a positive feedback loop as enhanced IL-12 secretion and 
costimulatory molecules presentation on DCs induces more CD40L expression on iNKT cells. 
This process finally results in the generation of mature APCs that can efficiently prime T 
cells68,69. 
As mentioned previously, the presentation of iNKT cell ligands by B cells to iNKT cells enhances 
the maturation of B cells and their antibody production70,71. Thus, on top on their adjuvant 
role on T cell immunity, iNKT cells are as well potent boosters of the humoral immunity 
provided by B cells. 
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G.2 CD8 T cell-mediated immunity 
CD8 T cells are cytotoxic lymphocytes playing a central role in the control of viral infections, 
intracellular pathogens and neoplasms by the adaptive arm of the immune system. Unlike 
iNKT cells, they express a very diverse range of TCRs enabling them to recognize a large panel 
of peptides on MHC-I molecules. Furthermore, in contrast to iNKT cells, CD8 T cells reach the 
periphery with a naïve phenotype and require antigen priming by professional APCs to acquire 
their effector functions72. 
G.2.1 The development of CD8 T cells 
Unlike B lymphocytes, which mature in the bone marrow, a portion of lymphoid progenitors 
migrate to the thymus where they acquire the T lymphocyte identity73. As these T lineage-
committed cells do not express yet either the CD4 or CD8 coreceptor, they are named DN for 
double-negative. DN T cells differentiate through 4 steps, identified by the expression of CD25 
and CD44: DN1 are CD44+ CD25-, DN2 are CD44+ CD25+, DN3 are CD44- and CD25+ and DN4 
are negative for both molecules74. DN3 thymocytes express a rearranged β TCR chain, which 
is expressed at the cell surface with a surrogate α chain75. A functional signalling by this pre-
TCR complex allows the thymocytes to undergo somatic rearrangement of the TCR α chain76,77. 
Late DN4 thymocytes express a T-cell receptor with a rearranged α and β chains which 
differentiate into the DP CD4+CD8+ stage78. 
DP thymocytes undergo several selection steps to ensure that their TCR is functional, reactive 
to self-MHC, but not reactive to self-derived peptide antigens. In the first selection process 
called positive selection, thymocytes bearing TCRs with weak reactivity for self MHC/peptides 
commit apoptosis because of insufficient TCR signalling. On the other hand, excessive TCR 
signalling also leads DP thymocytes to apoptosis during the negative selection step, allowing 
the removal of potentially harmful self-reactive T cells77. Finally, DP thymocytes undergo the 
lineage choice by losing the expression of either CD4 or CD8 provided they were selected by 
respectively MHC I or MHC II molecules, resulting in mature CD4+ or CD8+ SP thymocytes. 
Evidences have shown that the correct co-receptor choice to pair with the TCR is guided by 
differences in signalling through CD4 and CD879,80. Mature CD4 or CD8 SP T cells finally leave 
the thymus to the periphery. An overview of the steps of T cell development in the thymus is 
illustrated on Figure 5.  
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Figure 5 - Schematic representation of T cell development in the thymus. Adapted from 77. 
G.2.2 CD8 T cell priming and differentiation 
Naïve CD8 T cells continuously circulate between secondary lymphoid organs via the blood 
and lymph vessels where they patrol for DCs presenting antigens they are specific for81. DCs 
capture antigens in the periphery which when combined with the sensing of danger signals 
via TLR receptors, lead to their maturation in pro-inflammatory DCs trafficking to lymph 
nodes82. Hence the presentation of peptide antigens by mature DC to naïve T cells in 
secondary lymphoid organs is the initiating event of a T-cell response. The priming of T cells 
requires at least two signals. Signal 1 is the recognition of the MHC/peptide complex on the 
APC by the TCR and signal 2 is a costimulatory signal provided only by mature APCs, which is 
generally the ligation of CD28 by CD80 or CD8683,84. Upon priming, antigen-specific T cells 
clonally expand by dividing up to 20x. During this stage, CD8 T cells also undergo a 
differentiation process in which they acquire the expression of effector molecules, such as 
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Granzyme B, Perforin, Interferon γ and TNF α. They finally leave the secondary lymphoid 
organs to the periphery in order to kill infected cells at the sites of infection85.  This 
phenomenon is partly mediated by the downregulation of the selectin CD62L and the 
chemokine receptor CCR7, which are key homing molecules targeting T cells to secondary 
lymphoid organs. Instead, they express homing molecules targeting inflamed endothelium, 
such as CD44, which binds P- and E-Selectin and chemokines receptors, such as CXCR3, which 
facilitates the migration of effector cells towards inflamed tissues producing CXCL9/1086. But 
upon antigen clearance, most of effector CD8 T cells will die by apoptosis in a process called 
contraction and only a subset of effector CD8 T cells will survive and form a long-lasting 
memory T cell pool, able to quickly divide and form effectors upon antigen re-challenge by the 
same pathogen87 (Figure 6). In some infection models such as Listeria monocytogenes, it was 
demonstrated that at the peak of the effector response (i.e. when there is the highest 
frequency of effector CD8 T cells in the periphery), a population of effectors express high level 
of killer cell lectin-like receptor G1 (KLRG1) and are very susceptible to die during the 
contraction phase. They are called short-lived effector cells (SLECs). On the other hand, some 
cells express high levels of IL-7 receptor subunit-α (IL-7Rα or CD127) and are more likely to 
survive the contraction phase and become memory T cells. These cells are called memory 
precursor effector cells (MPECs)88,89. The remaining memory T cells do not require signalling 
via their antigen receptor and interleukin-2 (IL-2) to survive as it is the case for effector cells. 
In contrast, memory Cd8 T cells require IL-7 and IL-15, similarly to naïve T cells, which depend 
on IL-7 for their survival90.  
Different subsets of memory T cells exist. Indeed, central memory T cells reside solely in 
secondary lymphoid organs and have a great potency to proliferate and form a novel wave of 
effectors upon antigen re-encounter. Effector memory T cells are also found in secondary 
lymphoid organs, but also in the periphery.  Upon antigen re-challenge, they have a reduced 
proliferative capacity as compared to central memory cells, but they keep the expression of 
effector molecules87. Finally, a third subset of memory T cells has been identified, called 
resident memory T cells. These cells reside in the previously infected tissues and do not 
recirculate in secondary lymphoid organs or in other peripheral sites. They respond 
immediately to reinfection in those exposed tissues91. 
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Figure 6 - CD8 T cells clonally expand upon viral infection. Most of the effector T cells then die upon 
pathogen clearance. A fraction of these cells will survive to form memory cells. Adapted from 87. 
G.2.3 TCR Signalling 
The engagement of a T-cell receptor triggers a cascade of signalling events, which will 
determine the fate of the T cell, which will vary according to several factors such as the 
differentiation status of the cell or the engagement of co-stimulatory receptors. 
The TCR does not contain signalling modules by itself, but is associated with the CD3 complex 
on the cell surface, which consists of membrane proteins containing immunoreceptor 
tyrosine-based activation motifs (ITAMs). The triggering TCR signalling occurs when these 
ITAMs are phosphorylated by tyrosine kinases such as Lck and Fyn. Lck associates with the 
intracellular part of the CD4 or CD8 co-receptor and is brought close to the TCR upon contact 
of the TCR and co-receptor with the peptide-loaded MHC molecule on the APC92,93. 
Phosphorylated ITAMs by Lck and Fyn enable the docking of ZAP70, which is also 
phosphorylated by Lck and Fyn94. An important negative regulator of the initiation of these 
early events in TCR signalling is the phosphatase CD45, which dephosphorylates the proximal 
TCR signalling components and has to be excluded from the active TCR signalling complex95. 
The activated ZAP70 phosphorylates the scaffold protein LAT and the adapter protein SLP-
7696, which initiates the branching of the TCR signalling cascade towards three distinct 
pathways: NFAT, NF-κB and AP-1. For instance, the recruitment of phospholipase C γ (PLCγ) 
by LAT and SLP-76 will catalyse the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) 
into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). The messenger molecule IP3 
will trigger the release of calcium from the endoplasmic reticulum, leading to the activation 
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of NFAT, while DAG recruits and activates both Protein Kinase C θ (PKCθ) and RAS guanyl 
nucleotide- releasing protein (RasRGP), which respectively activate the NF-κB and AP-1 
signalling pathways. Finally, NFAT, NF-κB and AP-1 are the main transcription factors 
orchestrating the T cell response upon TCR triggering93,97. The main signalling events 
downstream of the TCR activation are depicted in Figure 7. 
 
Figure 7 - An overview of the early events in TCR signaling. TCR triggering recruits the kinases Lck and 
Fyn, which phosphorylate the CD3 complex, leading to the recruitment and the phosphorylation of 
ZAP70, which in turn phosphorylates LAT and SLP76. The next key step is the activation of PLC γ, which 
coordinates initiation of the signaling through 3 critical pathways: NFAT, NF-κB and AP-1. Adapted from 
93.  
G.2.4 T cell dysfunction: anergy, exhaustion and activation-induced cell death 
T cell anergy is an important mechanism of peripheral tolerance. It occurs when naïve T cells 
are primed without proper co-stimulatory signalling, such as CD2898 when interacting for 
example with tolerant DCs lacking CD80/86 expression. As a consequence, anergic T cells fail 
to proliferate, secrete IL-2 and exert effector functions99,100. Interestingly, anergy can be 
reverted by in vivo IL-2 treatment101. Molecularly, the TCR activation in absence of CD28 
signalling leads mainly to the NFAT signalling pathway, with a defect in AP-1 and NF-κB 
pathways. The regulation of transcription by NFAT is altered when AP-1 pathway is aborted, 
which prevents the expression of genes critical for T cell priming and effector differentiation, 
such as IL-2102. Indeed, CD28 mainly acts through the activation of the Phosphoinositide 3-
kinase (PI3K) pathway, which increases the activation of PLC γ, leading to optimal NF-κB and 
AP-1 signaling103–105. 
T cell exhaustion is, like T cell anergy, a dysfunctional state of T cells, which does not occur at 
the priming phase but in chronically stimulated effector T cells. It was first described by the 
 25 
group of R. Ahmed in a mouse model of chronic viral infection, in which they showed that 
chronic exposure to antigens led to a gradual loss of effector function and proliferation 
capacity in CD8 T cells106.  
The inhibitory receptor Programmed cell death 1 (PD1) was later shown to be an important 
player in the induction of T cell exhaustion, as the blockade of the interaction with its ligand 
PD-L1 could restore the function of T cells in a model of chronic infection107. Other factors also 
positively influence the onset of exhaustion in T cells, like the lack of CD4 T cell help108. 
Furthermore, it was later found that tumour-infiltrated lymphocytes (TILs) were often 
exhausted both in mice and human tumours and that in addition to PD-1, they co-expressed 
a broad set of inhibitory receptors, such as CTLA4, LAG3, TIM3 and BTLA. Indeed, the induction 
of T cell exhaustion in the tumour micro-environment (TME) is a major mechanism used by 
tumours to escape rejection by the immune system109,110. 
Alternatively, activation-induced cell death (AICD) is a crucial mechanism regulating the 
homeostasis of peripheral T cells. Upon activation, T cells upregulate both FasL and its 
receptor, Fas. Upon activation, T cells upregulate the apoptosis-mediating receptor Fas. 
Depending on their activation status (like costimulatory support), they can be more or less 
susceptible to Fas-mediated apoptosis. The triggering of AICD can occur via the expression of 
FasL on T-cells themselves (in the contraction process) or in immunopriviledged organs. 
Finally, other molecules such as TNF-α can induce AICD in certain circumstances111.  
G.2.5 PD1 signalling 
As previously explained, PD1 is highly expressed by exhausted T cells, but its expression is also 
increased upon TCR triggering112. The inhibitory action of PD1 mainly acts through its 
downstream effector SH2-domain containing tyrosine phosphatase 2 (SHP-2), which will 
prevent the phosphorylation of the early TCR signalling modules CD3, ZAP70 and PKCθ, but 
also PI3K, which is downstream of CD28113. The effect of PD1 signalling is seen as a reduction 
of effector function and survival114. 
PD-L1 is the main ligand of PD1 and its expression pattern is seen on both hematopoietic and 
non-hematopoietic cells. A variety of cells, including tumors, upregulate PD-L1 expression in 
response to IFNγ exposure114,115. But oncogenic signalling in tumors like increased PI3K activity 
through the loss of Phosphatase and tensin homolog (PTEN) does also enhance PD-L1 
expression116.  
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Interestingly, PD1 ligands also induce signalling in APCs. For example, PD-L1 and PD-L2 ligation 
on DCs reduces their maturation, resulting in an impaired T cell priming117. 
G.3 Cancer 
Cancer is the second cause of mortality worldwide and results from the abnormal proliferation 
of transformed cells, which then eventually invade other parts of the body, ultimately 
disrupting the organization and the function of the invaded structures118. 
G.3.1 Epidemiology of cancer 
Cancers are caused by genetic mutations, which can be inherited or generated in somatic cells. 
Certain viruses can also promote tumorigenesis by expressing viral oncogenes upon cell 
infection.  
Somatic mutations are caused by errors during DNA replication and by environmental cues. 
Indeed, the World Health Organization reported that “high body mass index, low fruit and 
vegetable intake, lack of physical activity, tobacco use, and alcohol use” are the cause of one 
third of cancer deaths. Furthermore, “cancer causing infections, such as hepatitis and human 
papilloma virus (HPV), are responsible for up to 25% of cancer cases in low- and middle-
income countries”119. These statistics emphasize the important role of environmental factors 
such as lifestyle and pathogens in the onset of cancer. However, random mutations occurring 
in somatic cells are estimated to be the main cause of cancer-causing mutations120. 
G.3.2 The development of cancer 
The development of cancer is a stepwise process in which transforming cells acquire key 
features allowing them to form local neoplasms (newly formed masses) and distant 
metastasis. In 2000, Hanahan and Weinberg have proposed a list of capabilities that a 
transforming cell need to acquire to form a tumor, referred as “hallmarks of cancer”121 (Figure 
8). In 2011, they adapted this list, taking into account the most recent knowledge in the 
understanding of cancer biology122.  
Some of these hallmarks are not intrinsically acquired by the tumor cells, but also by the 
stroma, which defines non-transformed cells recruited by the tumor and actively participating 
in the tumorigenesis122. The stroma is also referred as “tumor microenvironment” and is 
composed of a diversity of normal cells, such as macrophages, T cells, B cells and fibroblasts123. 
The first hallmark of cancer is the ability of tumor cells to sustain proliferative signalling. 
Indeed, cell proliferation is a tightly controlled mechanism that includes several checkpoints 
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to prevent abnormal cell proliferation. This can be overcome by the onset of mutations driving 
the constitutive activation of oncogenes (genes positively regulating the cell cycle). The next 
hallmark proposed by Hanahan and Weinberg is the evasion of growth suppressors: tumor 
suppressors are genes that negatively regulate the progression through the cell cycle, like p53, 
which ensures the control of cell division. Furthermore, the resistance to cell death is a 
hallmark which defines mechanisms involved in the resistance to apoptosis in cancer cells, via 
defective signalling pathways which generally lead to cell death. Another associated hallmark 
is the replicative immortality, by which tumor cells bypass the limited replicative capacity of 
normal cells, generally by expressing telomerase, an enzyme responsible for the maintenance 
of telomere length which controls cell longevity. The next hallmark is the ability of tumors to 
form new blood vessels, referred as the neovasculature, to allow the supply of oxygen and 
nutrients to the growing tumor mass. This capability is often provided by macrophages in the 
stroma124. Finally, a crucial hallmark of major interest in my project is the ability of tumors to 
escape elimination by the immune system, which will be described later in the introduction122. 
To summarize this part, transforming cells must acquire several characteristics to form 
tumors. Some of these characteristics are acquired by mutations in the tumor cells themselves 
and some others are provided by the recruited normal somatic cells, which form the tumor 
stroma. 
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Figure 8 - The hallmarks of cancer: these characteristics have been described by Hanahan and 
Weinberg as key features required for tumor initiation. Adapted from 122. 
  
G.3.3 Conventional cancer therapies 
Cancer patients are first treated with “conventional therapies”, either as single or combined 
treatments, depending on the tumor type, the tumor stage and the status of the patient. 
Conventional cancer therapies include surgery, radiotherapy and chemotherapy125. Recently, 
other treatments have emerged, such as targeted therapies, which target specifically 
oncogenic signalling in tumors rather than broad cytotoxic drugs such as chemotherapeutic 
agents126. When possible, these tumor targeting therapies have resulted in a reduced toxicity 
towards normal cells and thus lower off-target toxicity. 
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G.4 Cancer immunity 
The immune system was primarily shaped to discriminate self versus non-self in order to 
protect and tolerate its host while attacking invading pathogens such as bacteria or fungi. 
Despite the fact that tumors are self-derived, the immune system has developed mechanisms 
to recognize and attack them127. However, the antitumoral immunity is often insufficient to 
reject established neoplastic lesions, for reasons which will be explained in the next sections. 
The first pieces of evidence that the immune system plays a key role in the surveillance of 
tumors came in 1994 when a study showed that mice deficient for IFN γ receptor128 or for 
perforin, a cytotoxic effector molecule in T and NK cells, had a higher tumor incidence when 
treated with a carcinogen129. Few years later, the key role of lymphocytes in tumor 
immunosurveillance was demonstrated130. 
G.4.1 Cancer recognition by the innate immunity 
NK cells are  very important for the early control of viral infections, as unlike T lymphocytes, 
they can kill target cells without prior sensitization131. However, their role in the surveillance 
of malignant transformation has been demonstrated by several studies on carcinogen-
induced or transplanted tumors132,133.  
To recognize malignant or virally-infected cells, NK cells express a set of germline-encoded 
receptors. These NK receptors transmit either inhibitory or activatory signals to the NK cell, 
which altogether will decide whether the target will be killed or not131 (Figure 9). In mouse, 
the main inhibitory signalling molecules inducing NK cell tolerance are the receptors of the 
Ly49 family, which recognize MHC I molecules. Therefore, the loss of MHC I expression often 
occurring on tumor cells renders them more susceptible to NK cell-mediated lysis134,135. The 
activation of NK cells also depends on a wide set of receptors, which recognize stress signals 
on target cells that are virally infected or undergoing malignant transformation136. For 
instance, NKG2D binds to stress-related ligands upregulated upon DNA damage response in 
cancer cells or upon TLR stimulation in infected cells137. NK cells are also important mediators 
of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) through the recognition of the Fc 
domain of IgG1 antibodies by the CD16 receptor136. 
In addition to NK cells, myeloid cells such as granulocytes and macrophages are highly present 
in the tumor stroma. These myeloid cell subsets are highly plastic, and their effector functions 
depend on their environment and the signals they receive. For instance, upon microbial 
infection, macrophage activation occurs via exposure to IFNγ, which increases their 
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antimicrobial properties and their secretion of pro-inflammatory cytokines138.  Alternatively, 
macrophages exposure to Type-2 cytokines such as IL-4 and IL-13, was shown to also result in 
a high phagocytic activity but without secretion of pro-inflammatory cytokines139,140. The 
classical and alternative activation of macrophages were named M1 and M2, mirroring the 
Th1 and Th2 type of immune responses. More recently, it was shown that like IL-4 and IL-13, 
the immunosuppressive cytokines such as IL-10 and TGFβ also induced the M2 
phenotype141,142. The consensus today is that macrophage differentiation is rather a 
continuum between M1 and M2143. In tumors, M1 macrophages are pro-inflammatory, inhibit 
angiogenesis and support the adaptive immune response, while their M2 counterparts are 
immunosuppressive and support angiogenesis144,145. 
DCs also play an important role in tumor immunity by stimulating the T cell-mediated 
response. As for macrophages, the immunosuppressive stimuli in the tumor 
microenvironment induce a suppressive type of DCs characterized by the lack of T cell co-
stimulatory signals and the expression of the inhibitory molecules PD-L1, Arginase and IDO146. 
In order to acquire a pro-inflammatory phenotype and induce protective T cell responses, DCs 
need to sense Pathogen-Associated Molecules Patterns (PAMPs), which are generally lacking 
in the tumor environment. However, in certain conditions, tumor cell death can trigger DC 
maturation in a process called immunologic cell death (ICD). Indeed, although cell death does 
generally not induce an immune response, it can become immunogenic in certain 
circumstances. Indeed, the release of damage-associated molecular patterns (DAMPs) 
stimulates DCs to generate an immune response. DAMPs are certain cellular components, 
which are released upon apoptosis. Nucleic acids, ATP or heat-shock proteins are example of 
DAMPs147. For instance, the treatment of tumor cells with the chemotherapeutic agent 
anthracyclin induces an immunogenic cell death signal able to trigger an immune response. 
This signal critically depends on the DAMP Calreticulin (CRT), released by the dying tumor 
cells148. 
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Figure 9 - NK cells play a major role in tumor immunosurveillance. Lack of MHC I expression (missing 
self) decreases the inhibition of NK cells, leading to their activation. Alternatively, the upregulation of 
stress-related ligands on transformed cells activates NK cells cytotoxicity. Adapted from 149. 
  
 32 
G.4.2 Cancer recognition by the adaptive immunity 
The adaptive immune system encompasses B and T lymphocytes, which play a key role in the 
control of tumors. 
The main adaptive players in adaptive immunity-mediated tumor rejection are CD8 T cells. In 
a majority of tumors, like in colorectal cancer150, high T cell infiltration correlates with a better 
overall survival (OS) or progression-free survival (PFS). It is now clear that cancer patients 
mount T cell responses against tumor antigens, such as cancer-testis antigens (i.e. NY-ESO I), 
differentiation antigens (i.e. Melan A), and neoantigens (i.e. mutated epitopes)151,152. In order 
to mount an effective antitumoral T cell response, several steps need to be efficiently 
accomplished. They are described by Chen and Mellmann as the Cancer-Immunity cycle 
(Figure 10). The first step of the cycle is the released of tumor antigens, upon tumor cell death, 
and their processing by DCs. As said above, this step requires immunogenic signals to induce 
DC maturation. The next step is the DC antigen-presentation to T cells, resulting in the 
generation of effector CD 8 T cells. Primed T cells will traffic to the tumor, where they will 
exert cytotoxicity, release inflammatory signals and tumor antigens to feed the cycle. 
However, the Cancer-Immunity cycle is not optimally running in cancer patients, as their 
endogenous T cell response are not able to cure progressive disease 151. The aim of cancer 
immunotherapy is to optimize this cycle in order to improve the rejection of established 
tumors by the immune system. 
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Figure 10 - The cancer immunity cycle. This cycle was proposed by Chen and Mellmann to illustrate the 
single steps required to induce an effective antitumoral T cell response. Adapted from 151. 
G.4.3 The cancer immunoediting hypothesis 
The concept that the immune system is a sentinel of tumor formation is old153 and now widely 
accepted. However, despite the mechanisms of immune surveillance of tumors, cancer still 
arise in immunocompetent hosts. This can be explained by the cancer immunoediting 
hypothesis, proposed by Schreiber et al. Briefly, the immune response shapes the tumor as 
shown by several studies showing that tumors induced in an immunodeficient host grow 
slower when transplanted in an immunocompetent host, in contrast to tumors induced in an 
immunocompetent host, which are more aggressive130,154. As viruses, tumors have the ability 
to change and adapt because of their genetic instability. The pressure of the immune system 
drives the selection of variants that can withstand immune attack, for example by reducing 
their immunogenicity. Thus, the immune system does not only protect the organism against 
neoplasms, but it also shapes these neoplasms by selecting immune-resistant variants. In that 
view, Schreiber et al. propose three steps: the three Es of cancer immunoediting (Figure 11). 
The first E, Elimination, occurs when the immune system successfully rejects a tumor. 
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However, when the lesion persists and grows, the immune system may actively attack the 
tumor, as described by the second E: Equilibrium. The tumor is sufficiently big to generate a 
diversity of tumor cells, among which immune escape variants will be selected due to the 
pressure of the immune system. As a result, the third E: Escape describes the step in which 
only the tumor cells that highly resist to the immune system are selected and allow the 
progression of the disease155. 
 
Figure 11 - The three Es of cancer immunoediting describe the key steps of the selection of immune-
resistant tumors by the immune system attack. Adapted from 155. 
G.4.4 Immune escape mechanisms 
A big variety of mechanisms are used by tumors cells or by their supporting stroma to 
sabotage the cancer immunity cycle and counteract T cell-mediated rejection. For instance, in 
absence of immunogenic signals, tumor-derived DCs remain immature and tolerant and 
induce T cell anergy rather that effector differentiation156. It was even observed that 
peripheral DCs from cancer patients (out of the tumor bed) had defects in maturation as their 
DCs could not efficiently prime autologous T cells against tetanus toxoid or influenza peptides  
ex vivo, when compared to healthy donors.157. 
Myeloid-derived suppressor cells (MDSC) are important mediators of tumor 
immunosuppression, as immature myeloid precursor cells are rapidly recruited to the tumor. 
They exert their immunosuppressive functions through the secretion of the 
immunosuppressive cytokines TGF-β and IL-10 and the expression of the Arginase 1, which 
depletes L-Arginine from the stroma. They also produce nitric oxide through the expression of 
the iNOS enzyme158. 
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Defined subsets of lymphoid cells are also involved in tumor immunosuppression, among 
which the CD4+ regulatory T cells (Treg) are the best characterized. They are naturally 
occurring cells, unlike MDSC, and are considered as an important brake of the immune system 
to prevent excessive inflammation and autoimmunity. They are however hijacked by tumors 
to induce a tolerogenic environment. Tregs exert their suppressive activity through the 
secretion of Adenosine and the immunosuppressive cytokines IL-10 and TGF-β, cytolysis of 
effector CD8 T cells via Granzyme B and Perforin, local IL-2  depletion and the induction of 
tolerogenic DCs159. 
Another key immunosuppressive mechanism in tumors is the expression of PD-L1 by both 
tumor cells and stromal cells. Although PD-L1 expression is usually constitutive, it is largely 
induced by IFN-γ as a response to T cell attack160 (Figure 12). Its ligation on its receptor PD-1 
negatively regulates the activation of CD8 T cells, as described before. 
Another key effector of tumor immunosuppression is the enzyme Indoleamine 2,3-
dioxygenase (IDO), which is mainly expressed by myeloid cells and by the tumor cells 
themselves. IDO acts by recruiting MDSC and by depleting L-tryptophan, which is essential for 
effector T cell survival160. 
Finally, another example of immunosuppressive mechanism in tumors is the expression of 
FasL in the tumor endothelium, which kills T cells migrating to the tumor site. FasL expression 
does not occur in normal endothelium but is induced in the tumor neo-vessels as a 
consequence of the presence of immunosuppressive factors161. 
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Figure 12 - PD-L1 is induced by IFNγ and is therefore upregulated by tumor cells upon T cell attack. It 
is therefore a key mediator of the immune adaptive resistance, as it serves as a molecular shield to 
protect tumor cells from T cells. Adapted from 162. 
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G.5 Cancer immunotherapy 
The principle of cancer immunotherapy relies on the use of the host immune system to attack 
tumors, and can be subdivided into two categories: active and passive immunotherapy. Active 
immunotherapy takes advantage of the immune system of the host to mount an antitumoral 
response, giving the possibility to generate an immunological memory as well, like cancer 
vaccines. Passive immunotherapy does not rely on the generation of an immune response and 
instead provides the molecules or the effector cells, such as respectively therapeutic antibody 
treatments and the adoptive transfer of effector T cells. However, the frequent combination 
of several therapies makes this distinction obsolete. 
Immunotherapy was discovered more than 100 years ago by William Coley, when he obtained 
complete remission of several cancer patients by injecting in the tumors the live bacteria 
Streptococcus pyogenes. However, this protocol was rapidly abandoned because of its toxicity 
and its unknown mechanism of action, and surgery and radiotherapy became standard of 
care163.  
In 1976, the idea to use bacteria to treat cancer was again exploited for the treatment of 
bladder cancer via the intra-vesical instillation of the Bacillus Calmette-Guérin (BCG) 
tuberculosis vaccine. This protocol is still indicated for the treatment of non-muscle-invasive 
bladder cancer, and the major local inflammation prevents tumor recurrence in 70% of 
patients164,165. A key event in the history of immunotherapy was the cloning in 1999166 of the 
melanoma-derived antigen MZ2-E (MAGE-A1), which was associated with antigen-specific T 
cell responses in several melanoma patients, showing that tumor-derived antigens can be 
targeted by T cells.Another milestone was the approval of T cell-stimulating cytokine IL-2  by 
the FDA also in 1999 for the treatment of metastatic melanoma167,168. Recent strategies 
include adoptive T cell therapies and checkpoint blockade treatments, which will be described 
below. 
G.5.1 Therapeutic Cancer vaccines  
Therapeutic cancer vaccines aim to generate or amplify an antitumoral T cell response. A 
vaccine requires one or multiple antigens and an adjuvant, which makes the antigens 
immunogenic by activating the innate immune system. 
Different vaccine strategies have been tested in clinical trials, but often with moderate 
efficacy. Several reasons can explain this limited success. First, most tumor-associated 
antigens (TAAs) are self-antigens expressed by somatic cells and overexpressed by cancer 
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cells. Thus, central tolerance mechanisms preclude the generation of high affinity T cells 
towards these antigens. Second, strong adjuvants need to break the peripheral tolerance 
towards tumor-derived antigens in tumors. Third, cancer immunoediting mechanisms select 
tumor cells that are poorly immunogenic169, and the immunosuppressive tumor environment 
generate the so-called exhausted T cell phenotype seen in tumor-infiltrating T cells.  
So far, a large number of clinical trials have and are testing therapeutic cancer vaccines. 
However, very few have proven to efficiently improve the survival of cancer patients and have 
been moved to clinical application. 
For instance, the Sipuleucel-T therapeutic was FDA-approved in 2010 for the treatment of 
metastatic castration-resistant prostate cancer170. Briefly, APCs and peripheral blood 
mononuclear cells (PBMC) are pulsed with a fusion protein made of the prostate acid 
phosphatase antigen and the granulocyte-macrophage colony-stimulating factor (GM-CSF). 
The cell suspension is then injected into the patients. Another strategy tested in a phase II 
clinical trial, made use of viral vectors encoding the prostatic antigen PSA, the co-stimulatory 
molecule CD80 and the adhesion molecules LFA-1 and ICAM-1. The viral system allowed the 
in vivo delivery of genes and acted as a strong adjuvant171. 
Several clinical trials involving therapeutic vaccines were also conducted in breast cancer 
patients. in particular a phase II trial involving a HER2-derived peptide formulated with GM-
CSF172. 
Concerning lung malignancies, several vaccination strategies have been tested, with however 
poor clinical outcome. For instance, Tecemotide, which contains a peptide derived from the 
TAA antigen MUC1 and the adjuvant monophosphoryl lipid A (MPL), failed to significantly 
improve the survival of patients with unresectable non-small-cell lung cancer (NSCLC)173. 
In view of the immunogenicity of melanoma tumors, therapeutic vaccines have also been 
clinically tested, such as a phase II clinical trial combining systemic IL-2 administration and 
vaccination with the TAA antigen gp100 formulated with the adjuvant Montanide™ ISA 51, 
which led to  significant improved the survival of melanoma patients174. Another strategy 
implied the loading of peptides derived from the gp100 and tyrosinase melanoma-associated 
TAAs on autologous DCs before reinfusion into the patients, showing also clinical beneficial 
clinical outcome175. Finally, a phase II trial on melanoma patients showed that the delivery of 
the cancer-testis (CT) antigen NY-ESO-1, expressed in various tumors, by viral vectors 
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significantly improved the survival of the patients, yielding 14% of objective response rate and 
52% of disease stabilisation176. 
G.5.2 Neoantigens 
As described before in the introduction, the high mutational load in the tumor cells generates 
a panel of mutated proteins called neoantigens, of which peptides can be detected by the CD8 
T cells of the host and generate a specific antitumor response. In mouse tumor models, it was 
demonstrated by the group of Schreiber that checkpoint blockade therapies promote tumor 
regression mainly by enhancing the activity of neoantigen-specific T cells177. The same is true 
in cancer patients as it was reported that high mutational load is associated with better 
response to checkpoint blockade therapy in melanoma, colon cancer and NSCLC178–180. 
Progresses in sequencing technology and in predictive tools able to select mutations with high 
probability of being presented on the MHC molecules on tumor cells will allow to generate 
personalized vaccines targeting mutations specifically displayed by tumors in individual 
patients. A very recent trial has tested the feasibility of this strategy and showed very 
encouraging clinical results in a cohort of melanoma patients181. 
G.5.3 Tumor lysates 
Another approach to elicit an antitumoral T cell response is to inject ex vivo-matured DCs 
loaded with tumor lysates. The rationale is that the DCs will present mutated antigens specific 
to the tumor of the patient which will elicit a T cell response against the specific antigens 
presented by the tumor. This strategy has been tested by the group of Prof G. Coukos in a 
phase I clinical trial with patients bearing recurrent ovarian cancers and showed modest but 
encouraging efficacy182. This strategy is very promising as it will allow to vaccinate patients 
specifically against their own tumor antigens without the need to sequence and analyse the 
mutanome of their tumors, which would be much faster and cost-effective. 
G.5.4 iNKT cells in cancer 
It is now evident in both mouse and humans that iNKT cells play a role in tumor 
immunosurveillance. For instance,  mice lacking iNKT cells have a higher onset of spontaneous 
tumors induced by a deficiency of p53149. The role of iNKT cells in tumor immunosurveillance 
has been outlined as well in different models183,184 and cancer patients often display reduced 
iNKT cell number and defective activation185,186. 
 40 
On top of tumor immunosurveillance, iNKT cells can be harnessed against cancer by exploiting 
their transactivating properties of the innate and adaptive arms of the immune system, as 
described in G.1.9. 
It was first demonstrated that the injection of αGalCer in mice bearing EL4 or B16 tumors 
prolonged their survival. As well, a group demonstrated that in a mouse myeloma model, the 
injection of irradiated tumor cells loaded with αGalCer in tumor-bearing mice promoted the 
regression of the implanted tumors by inducing both a humoral and a cytotoxic antitumoral 
response187.  
The groups of V. Cerundolo and others demonstrated the potent adjuvant role of αGalCer as 
an adjuvant for therapeutic cancer vaccines. For instance, they showed that the combined 
presentation of the OVA antigen and αGalCer by DCs effectively raised an in vivo OVA-specific 
CD8 T cell response able to control established OVA-expressing tumors65. 
Alongs the same line, our group has demonstrated that iNKT cells can be targeted to the 
tumors via fusion proteins made of a tumor-targeting antibody single chain such as HER2 and 
of CD1d, loaded with αGalCer. These fusion proteins were able to induce the recruitment of 
iNKT cells to the tumor site and induce tumor regression. Furthermore, the combination of an 
anti-HER2/CD1d fusion protein with OVA/CpG vaccination in a tumor model expressing both 
HER2 and OVA synergistically expanded OVA-specific T cells, NK cells, increased the serum 
levels of IL-12 and promoted a strong control of the tumor55,56,188.  
The group of François Trottein has also shown that targeted iNKT cell activation with the co-
delivery of peptide tumor antigens and αGalCer to CD8α DCs induces a very strong T cell 
immunity and tumor rejection189. 
iNKT cells can also have a direct effect on the tumor stroma. Indeed, the group of Metelitsa 
has highlighted in a xenograft model of neuroblastoma190, that iNKT cells can kill tumor-
associated macrophages (TAMs), when loaded with tumor lysate.  
Since iNKT cells have proven to be potent immunotherapeutic agents in mouse models, 
several clinical trials have been conducted to harness iNKT cells in human cancer patients. A 
clinical trial has evaluated the effect of the injection of αGalCer-loaded mature DCs in cancer 
patients. This treatment significantly increased the IL-12 concentration in serum and 
promoted the proliferation of iNKT cells. There was also evidence of T cell transactivation as 
seen by the expansion of CMV-specific CD8 T cells in some patients191. Another study 
combined the administration of ex vivo-expanded iNKT cells and αGalCer-loaded DCs in cancer 
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patients. Although, the cohort of treated patients was rather small, this treatment resulted in 
the regression of the tumors in half of them192. 
G.5.5 Checkpoints blockade 
In 2013, the world’s leading Science magazine nominated immunotherapy as the 
breakthrough of the year, following the discovery of checkpoint blockades as 
immunotherapeutic agents (Figure 13). 
 
 
Figure 13 - Science nominated cancer immunotherapy as the « breakthrough of the year » in 2013, 
following the discovery of checkpoint blockades as immunotherapeutic agents. “Antibodies (pink) 
zoom toward a T cell (gray, with CTLA-4 receptor proteins shown in light blue), giving the T cell a push 
to attack tumor cells. Legend and picture are adapted from 193. 
Checkpoint blockades refer to antibodies that specifically target molecular brakes on T cells 
to prevent their activation by ligand binding. They are effective for CTLA-4 and PD1 receptors 
blockade. 
CTLA-4 is a receptor which is almost exclusively expressed on T lymphocytes upon T cell 
activation194. CTLA-4 binds to the same ligands CD80 and CD86 expressed on APCs, as CD28, 
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although with a higher affinity195. Because of its structural similarity to CD28, CTLA-4 was first 
believed to be a co-stimulatory molecule196. It was however later discovered that CTLA-4 
inhibits T cell activation first by competing with CD28 for the costimulatory ligands CD80 and 
CD86 presented on APCs, depriving T cells of costimulation. Second, CTLA-4 recruits the SHP-
2 phosphatase, which decreases the phosphorylation of the proximal TCR signaling complex, 
whereby it dampens T cell activation and also reduces IL-2 production and cell division196,197.  
Ipilimumab is a monoclonal antibody blocking CTLA-4. In 2010, a phase III clinical trial with 
stage III and IV melanoma patients demonstrated that Ipilimumab could significantly improve 
the survival of patients vaccinated with the TAA antigen gp100, as compared to vaccination 
alone198. In the same time, another clinical trial showed that Ipilimumab plus the 
chemotherapeutic agent dacarbazine significantly improved the overall survival of melanoma 
patients compared to dacarbazine alone199. Finally, Ipilimumab (Yervoy) was FDA-approved in 
2011 for the treatment of unresectable or metastatic melanoma.  
PD1 is another checkpoint in T cells and its mechanism of action has been described above 
(Chapter G.2.5). PD-1 is up-regulated on T cells during chronic inflammation such as occurring 
in tumors, and its binding to PD-L1 and PD-L2 on tumor cells, render T cells exhausted and 
dysfunctional 200.   
Two anti-PD1 monoclonal antibody have been approved by the FDA to treat cancer: the first 
one, Nivolumab, from Brystol-Myers Squibb and the second one, Pembrolizumab from Merck. 
Nivolumab was the first anti-PD1 treatment to show efficacy for multiple cancers. It was able 
to induce up to 40% of objective response rate (ORR) in patients with metastatic 
melanoma201,202. It was also tested in patients with squamous non-small-cell lung carcinoma 
(NSCLC) and its efficacy was demonstrated to be superior than standard chemotherapy in this 
disease203. Its competitor, Pembrolizumab, was also extensively tested and shown to be 
efficient for melanoma204, NSCLC205, head and neck cancers206 and triple-negative breast 
cancers207. 
Finally, the combination of CTLA-4 and PD-1 blockade has also been investigated in metastatic 
melanoma patients and was shown to be even more efficient than the single drugs alone, with 
however more important immune-related toxicities208–210. In addition, recent data showed 
that anti-PD1 treatments for metastatic melanoma are more efficient and cause less adverse 
effects than anti-CTLA-4204. 
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G.5.6 TILs therapies 
Adoptive T cell therapies involving the transfer of tumor-infiltrating lymphocytes were first 
tested in mice thirty years ago by the group of S. Rosenberg. They showed that lymphocytes 
extracted from various types of tumors could be expanded ex vivo using IL-2 before being re-
infused into the tumor-bearing hosts to mediate tumor rejection211. They later demonstrated 
that transferred TILs were more than 50x more efficient at rejecting established tumors than 
IL-2-activated peripheral blood lymphocytes212. In 1988, the first clinical trial involving TILs 
therapy in cancer patients was published and displayed encouraging results, as a subset of the 
patients experienced tumor regression with minimal side effects213. Later, TILs therapy was 
improved thanks to a better understanding of the biology of T lymphocytes. Indeed, prior-
lymphodepletion of the host and recombinant IL-2 infusions allowed a better engraftment, 
survival and antitumoral activity of the transferred T cells214. Several additional clinical trials 
have been conducted in patients with metastatic melanoma. The refinement of the protocols 
for the culture and selection of tumor-reactive TILs, for the patient pre-conditioning and for 
the transfer TILs together with IL-2 administration allowed to strongly increase the efficacy of 
the therapy. Indeed, in 2008, in a trial on metastatic melanoma, 70% of overall response rate 
(ORR) was achieved within the group of patients that received the most radical 
lymphodepletion, with some patients experiencing complete remission215. An example of the 
response of a melanoma patient to TIL therapy is presented on Figure 14. 
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Figure 14 - Example of a spectacular response in a patient suffering from metastatic melanoma, treated 
with autologous TIL within a clinical trial conducted by the group of Rosenberg. Adapted from 216. 
TIL therapies have shown also encouraging results in other malignancies like in ovarian 217 and 
cervical214 cancers. 
G.5.7 CAR T cells  
Chimeric antigen receptors (CARs) are artificial proteins constructed from an antigen 
recognition domain, made of an antibody single chain (scFv), a hinge region and a 
transmembrane domain, generally derived from CD8α or CD28. The intracellular part of a CAR 
comprises T cell-signalling domains.  First generation CARs only include CD3ζ, while second 
generation CARs add a co-stimulatory domain on top of CD3ζ, generally 4-1BB or CD28. Third 
generation CARs use two co-stimulatory domains (Figure 15). CARs are transduced into 
peripheral blood-derived autologous CD8 T cells with replication-incompetent γ-retroviruses 
or lentiviruses218. T cells are then expanded ex vivo and infused back to the patient in 
combination with a lymphodepleting chemotherapy219 (Figure 16). 
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Figure 15 - Structure of a chimeric antigen receptor. Adapted from 220. 
 
CAR T cell-mediated immunotherapies show very impressive results for the treatment of B cell 
malignancies. The first report of a patient successfully treated with CAR T cells was published 
in 2010. This patient after multiple-relapses of follicular lymphoma received a 
lymphodepleting chemotherapy followed by the infusion of autologous CTLs transduced with 
a second generation anti-CD19 CAR, which target the CD19 surface molecule on B cells and 
most B cell-derived malignancies221. In another study by the same group, it was demonstrated 
that CD19 CAR CTLs could efficiently eliminate lymphoma masses as well as tumor cells in the 
bone marrow, resulting in long term remission. This impressive clinical  efficacy is however 
often associated with significant systemic toxicities caused by an important rise in the level of 
serum pro-inflammatory cytokines such as TNF-α, leading to the so-called cytokine-release 
syndrome (CRS)218. 
It is important to note that first generation anti-CD19 CAR T cells containing only the CD3ζ 
activatory domain failed to eradicate tumors in patients with follicular lymphomas because 
these cells could not expand and persist well in vivo222,223. Mostly, CD28 and 4-1BB are used 
as costimulatory domains in second generation CARs. 4-1BB was however shown to improve 
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more T cell persistence than CD28224–226. Later, multiple clinical trials involving patients with 
B cell malignancies have been conducted with second generation CD19 CAR CTLs, showing 
sometimes up to 60% of complete responses218. Recently, Novartis received the FDA approval 
to treat B cell lymphomas with a CD19 second generation CAR originally developed at the 
University of Pennsylvania227.  
Despite the very impressive results of CAR T cell therapy against haematological malignancies, 
clinical trials using CAR T cells to treat solid tumors have so far failed to demonstrate efficacy. 
Indeed, unlike CD19 in B cell malignancies, it is less obvious to find surface antigens expressed 
homogeneously by most tumor cells in a solid tumor and not by normal somatic cells. 
Furthermore, migration of CAR T cells into solid tumors is often inefficient because they lack 
the appropriate chemokine receptors required to enter the lesion. Finally, solid tumors are 
highly immunosuppressive (as describe above) and preclude the normal lytic function and 
survival of CAR T cells228. 
Yet, multiple clinical trials are testing the optimization of CAR therapy for solid malignancy. 
For instance, EGFRvIII is a mutated form of the epithelial growth factor receptor (EGFR), 
expressed solely on tumor cells in certain glioblastomas and is tested in a phase I clinical 
trial229. Another example is the Human Epidermal Growth Factor Receptor-2 (HER2), which is 
expressed at low level on somatic cells, but overexpressed on certain malignancies such as 
breast cancers230. Unfortunately, the low level expression of HER2 on lung epithelial cells led 
to fatal respiratory distress in a case report of a patient with metastatic colon cancer treated 
with anti-HER2 CAR T cells231. However, another study showed no toxicity but only moderate 
efficacy of anti-HER2 CAR therapy in patients with sarcoma232. 
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Figure 16 - The complex preparation of CAR T cells: T cells are collected from peripheral blood and 
purified. They are next activated with beads coated with anti-CD3 and CD28 antibodies and transduced 
with lentiviruses encoding for the CAR. Then, T cells are expanded, tested and reinfused in the patient. 
Adapted from 219. 
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H My PhD projects 
Cancer immunotherapy comprises several strategies to generate an antitumoral immune 
response, such as cancer vaccines, checkpoints blockade or T cell engineering. These 
immunotherapy modalities target different aspects of the T cell-mediated antitumoral 
response.  
My PhD thesis involved three main projects, which encompassed these three strategies of 
cancer immunotherapy.  
The first two projects were devoted to the study of iNKT cells. Indeed, our laboratory has a 
strong expertise in exploiting iNKT cells against cancer, and in particular their adjuvant 
properties on the adaptive immune response. However, their rapid anergy induction after an 
initial strong activation by the CD1d/iNKT agonist αGalCer has so far limited their clinical use. 
Therefore, my first project has focused on the understanding of iNKT cell anergy, which may 
allow improving the manipulation of these non-conventional lymphocytes in therapeutic 
cancer vaccines. 
My second project was also related to iNKT cells with the development of a DC vaccine. The 
adoptive transfer of ex vivo generated DCs pulsed with an antigen and/or cytokines have now 
entered clinical application in cancer immunotherapy and have provided promising results 
when involving the transactivation of iNKT cells. In this context, I tested an innovative 
combined treatment involving a DC/αGalCer vaccine and PD-1 checkpoint blockade.  
Finally, my third project was related to CAR T cell engineering. While CAR T cell therapy have 
entered the clinics for the treatment of B cell malignancies, it still needs optimization for the 
treatment of solid malignancies. Several groups including ours aimed at combining the 
activation of a CAR and the endogenous TCR on the same T cell to improve the activity of CAR 
T cells. In this project, I investigated how the T cell receptor copes with the presence of the 
CAR and if the presence of the CAR disturbs the activation of the T cell when engaged via its 
TCR. 
Altogether, the general purpose of my PhD thesis was to optimize T cell-mediated cancer 
immunotherapy either via cancer vaccine or T cell engineering. 
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I Regulation of iNKT cell anergy 
I.1 Aim 
iNKT cell anergy, which is described in the introduction, is a hurdle for efficient iNKT cell-
mediated immunotherapy. Indeed, a single dose of αGalCer in mice renders iNKT cells 
hyporesponsive to subsequent treatments49. Furthermore, a proportion of anergized iNKT 
cells acquire a regulatory phenotype, which promotes tumor tolerance49. As discussed in 
6.1.7, several molecular players have been demonstrated to play a role in the onset of anergy 
in iNKT cells, such as PD-1 up-regulation, the lack or excess of co-stimulation to iNKT cells by 
APCs50–53. However, no clearly-defined mechanism has been proposed so far to explain the 
molecular mechanisms behind iNKT cell hyporesponsiveness. Interestingly, our previous 
results demonstrated that CD1d-antitumor fusion proteins induce a fast and sustained iNKT 
cell activation, which allowed repeated treatments55,56. Similarly, we and others showed that 
Th2 GSLs which quickly load on the APC cell surface, resulted in diminished iNKT cell anergy 
(unpublished, and 54). 
In view of these results, we investigated the mechanisms of iNKT cell anergy induction by 
comparing analogs of αGalCer inducing either a Th1 or a Th2 response.  
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I.2 Material and methods 
I.2.1 B cell isolation 
To isolate B cells, C57BL/6 spleens were smashed on a 40μm cell strainer. Red blood cells were 
lysed in RBC lysis buffer (Qiagen 158904) for 5min and then washed in full medium. After that, 
Fc receptors were blocked for 20min using the supernatant of the rat anti-mouse CD16/32 
2.4G2233 hybridoma. Cells were then stained with 5μg/ml CD19-FITC (Biolegend 115506) for 
30min and then washed 3 times in FACS buffer (PBS, 5% FCS and 5mM EDTA). Finally, B cells 
were sorted with anti-FITC microbeads according to the manufacturer protocol (Miltenyi 130-
048-701).  
I.2.2 DC isolation from spleen 
DCs were isolated from the spleens of Flt3L transgenic mice234. Spleens were harvested and 
digested by injecting 0.32mg/ml Liberase and 0.12 mg/ml DNAse in plain RPMI medium and 
incubated for 20min at 37°C. The organs were then smashed on a 100μm cell strainer. Red 
blood cells were lyzed and Fc receptors blocked as described above. Finally, DCs were sorted 
with CD11c microbeads (Miltenyi 130-108-338) according to the manufacturer protocol. 
I.2.3 DC generation from bone marrow 
To generate DCs from bone marrow, the bones from the back legs of C57BL/6 mice were 
collected, isolated from muscles and washed in full media. The bone marrow was flushed out 
with a 1ml insulin syringe (Beckton Dickinson 324912) and filtered through a 100μm cell 
strainer.  Red blood cells were lyzed as described previously. 2x106 cells were plated in each 
well of a 6 well plate in 5ml of IMDM medium supplemented with 10% FCS, 50U/ml Penicillin-
Streptomycin (Gibco 15070-063), 0.075% Sodium Bicarbonate (Thermo Fisher Scientific 
25080094), 10mM HEPES (Gibco 15630080), 1x MEM NEAA (Gibco 11140050), 50μM β-
mercapto-ethanol (Gibco 31350010), 10 ng/ml recombinant mouse GM-CSF (Peprotech) and 
20 ng/ml recombinant mouse IL-4 (Peprotech). The medium was changed on day 3 and 5. Cells 
were harvested on day 6. PBS-5mM EDTA was used to detach the DCs that were generated. 
I.2.4 GSL loading on APCs  
To pulse APCs with αGalCer analogs, GSLs were first heated for 5min at 65°C to reduce micelles 
before dilution. Cells were incubated with 200ng/ml GSLs (or less, depending on the 
experiment) for 20h in full medium. The proper loading of GSLs was verified by flow 
cytometry: the cells were washed, incubated with the FcR blocking supernatant as described 
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previously and incubated for 20min on ice with 2μg/ml of L363-PE antibody (Biolegend 
140505). Cells were washed twice with FACS buffer prior to cytofluorimetric acquisition. 
Depending on the experiment, the cells were fixed before or after the loading of GSLs: cells 
were washed twice in cold PBS and incubated for 10min on ice in PBS 2% paraformaldehyde. 
The cells were then washed twice in cold complete medium. 
I.2.5 Restimulation in vivo and flow cytometry analysis of iNKT cells 
To assess the anergy status of iNKT cells, mice were re-challenged i.v. with 0.8 to 1μg of DB03-
4 or KRN7000 depending on the experiment. The animals were sacrificed 3h later and spleens 
were harvested and smashed through a 70μm filter. Red blood cells were lysed as described 
previously. Single cell suspensions were put in culture at 37°C in full medium for 4.5h with 
Golgi Stop (BD Biosciences 554724) and Golgi Plug (BD Biosciences 555029), both at a 1:1000 
dilution. Afterwards, cells were stained for flow cytometry analysis: dead cells were excluded 
with Fixable Viability Dye eFluor™ 506 (eBioscience 65-0866-14). iNKT cells were gated using 
CD3e-Alexa Fluor 700 (Biolegend 100215) and CD1d/αGalCer multimer PE (home-made), and 
B cells were excluded with the B220-APC antibody (Biolegend 103211). To stain for 
intracellular cytokines, cells were fixed using a fixation buffer for intracellular staining 
(Biolegend 420801) according to the manufacturer protocol, before being stained with the 
antibodies IFNγ-PerCP/Cy5.5 at 0.5μg/ml (Biolegend 505821), TNFα-Pacific Blue at 1μg/ml 
(Biolegend 506318) and IL-10-PE/Cy7 at 1μg/ml (Biolegend 505025) diluted in 
permeabilization buffer (Biolegend 421002) for 30min on ice. Cells were finally washed twice 
in permabilization buffer and resuspended in FACS buffer prior to acquisition.    
I.2.6 Serum cytokines measurement 
To measure the serum levels of IFN-γ, blood was collected from the tail veins and centrifuged 
in microvette tubes to separate the serum from the cells (Sarstedt 20.1344). IFN-γ was 
assessed with the ELISA Ready-SET-Go kit (eBioScience 50-173-19).  TNF-α and IL-6 were 
measured by flow cytometry using the Mouse Th1/Th2/Th17 Cytokine Kit (BD Biosciences 
560485).  
I.2.7 CD1d and lipid raft flow cytometry analysis on APCs 
CD1d levels were analyzed using the anti-CD1d-PerCP/Cy5.5 (BioLegend 123513) at the 
concentration of 1μg/ml for 20min on ice. Lipid rafts were stained with Cholera Toxin B 
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labelled with Alexa Fluor 647 (Thermo Fisher Scientific C-34778) at the concentration of 
2μg/ml for 20min on ice.  
I.2.8 DC vaccination and OT-1 T cell transfer 
To vaccinate mice, DCs were generated from bone marrow as described previously. They were 
then loaded for 20h with the OVA SIINFEKL peptide at the concentration of 10μM together 
with 200ng/ml of either DB03-4 or KRN7000. The cells were then washed 3 times and 
resuspended in plain RPMI medium for i.v. injection. 
OT-1 CD8 T cells were extracted from the spleen of OT-1 transgenic mice235. CD8 T cells were 
purified using the EasySep™ Mouse CD8+ T Cell Isolation Kit (StemCell 19853) according to the 
manufacturer protocol. 
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I.3 Results 
I.3.1 Th1 and Th2-biasing αGalcer analogs with different kinetic of iNKT cell activation 
To investigate the onset of anergy induction in iNKT cells by Th1 and Th2-biasing αGalCer 
analogs, we focused on two GSLs, DB03-4 and KRN7000. While KRN7000, originally isolated 
from a marine sponge, induces a mixed Th1/Th2 response in iNKT cells, DB03-4 skews the iNKT 
cell response towards Th2236. In addition to the cytokine profile, B cells incubated with 
200ng/ml of DB03-4 or KRN7000 showed very different kinetic of presentation, as monitored 
with the antibody L363, specifically recognizing CD1d when loaded with αGalCer237. Indeed, 
DB03-4 is presented at the cell surface after already 2h, while the presentation of KRN7000 is 
delayed, as it appears at 20h (Figure 17 A). The same kinetic of iNKT cell activation occurs in 
vivo. Mice received either 1μg of DB03-4 or KRN7000 i.v. and serum was collected at 2h and 
21h. IFNγ was measured by ELISA as a surrogate of iNKT cell activation. At 2h, DB03-4 induced 
more IFNγ than KRN7000, while the opposite pattern was observed at 21h (Figure 17 B). These 
results support the hypothesis that Th2-biasing glycolipids are presented faster than their Th1 
counterparts as they can load directly on CD1d at the cell surface without requiring 
internalization44.    
 
 
Figure 17 – Different kinetics of the two αGalCer analogs DB03-4 and KRN7000. A) B cells were 
incubated at 37°C with 200ng/ml of either DB03-4 or KRN7000 for 2h and 20h. The dot plots indicate 
the loading or not of αGalCer on CD1d by L363 mAb staining. B) C57BL/6 mice received 1μg of either 
DB03-4 or KRN7000 i.v. and were bled at 2h and 21h. Serum IFNγ was measured by ELISA.   
To investigate the whether DB03-4 or KRN7000 differentially induce iNKT cell anergy, we 
challenged mice 3 times with each of the GSLs. We performed a cytokine measurement in the 
serum of mice 6h after the first injection of DB03-4 or KRN7000, which shows that the two 
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GSLs induce IFNγ and TNF-α, while only KRN7000 induces IL-6 at this time point (Figure 18). 
However, 3h after the 3rd GSL injection, only mice that received DB03-4 display a secretion of 
these cytokines in the serum. These results show that repeated injections of DB034 induce 
less iNKT cell anergy than KRN7000. 
 
 
Figure 18 - DB03-4 keeps iNKT cells responsive to multiple challenges. Serum cytokines measured in 
mice 6h after the first and 3h after the third injection of either DB03-4 or KRN7000. 
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I.3.2 Th2/polar αGalCer analogs induce less iNKT cell anergy than their Th1/apolar 
counterparts 
To extend the notion that Th1 and Th2 αGalCer analogs induce differential iNKT cell anergy, 
we studied a panel of αGalCer analogs, which differ in their solubility as a result of slight 
structural differences in their lipid tail (Figure 19). c-GC, KRN7000 and SKC08-27 are apolar 
analogs and induce preferentially a Th1 response, while DB03-4, DB05-14, DB03-5 and 
BF1308-84 are Th2-skewed. Finally, 7DW8-5 has a mixed phenotype.  
 
Figure 19 - Chemical structure of the αGalCer analogs tested in this project. 
C57BL/6 mice were injected twice with 0.4μg of glycolipids i.v. on day 0 and 5. They were then 
rechallenged with a dose of 0.8μg of each of the GSLs (Figure 20 A). Three hours after the 3rd 
challenge, iNKT cells failed to upregulate the activation marker CD69 after repeated injections 
of Th1 analogs, while its expression remained high with Th2-biasing GSLs (Figure 20 B). The 
same pattern was also observed with intracellular INFγ. These results show that Th2 
glycolipids induce significantly less iNKT cell anergy than Th0/1 analogs. 
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Figure 20 – The hydrophobicity of αGalCer analogs controls the induction of iNKT cell anergy. A) 
Schematic representation of the experiment: mice received two doses of 0.4μg of each of the GSLs at 
day 0 and 5. They were rechallenged on day 13 with 0.8μg of each GSLs and cytokine accumulation in 
spleen iNKT cells was monitored by flow cytometry. B) Surface staining of CD69 and intracellular 
cytokine staining of splenic iNKT cells after 3 injections of GSLs. 
I.3.3 Professional and non-professional APCs similarly induce iNKT cell anergy when loaded 
with KRN7000 
The group of Kronenberg demonstrated that professional APCs such as DCs induce more iNKT 
cell anergy than other APCs such as B cells51. Later, the group of Kronenberg showed that 
neither B cells or DCs were required for the induction of iNKT cells in vivo and that it could be 
induced by an unidentified hematopoietic population54. However, we do not confirm these 
findings. 
To evaluate the affinity of different APCs for polar and apolar GSLs, splenocytes were loaded 
with DB03-4 or KRN7000 for 20h to evaluate the GSL presentation in several APC populations. 
Interestingly, the L363 staining showed that B cells and CD8α- DCs presented more efficiently 
DB03-4 than CD8α+ DCs. However, CD8α+ DCs were the most efficient APCs at presenting 
KRN7000 (Figure 21).  
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Figure 21 - APCs have different affinities for the polar and apolar GSLs DB03-4 and KRN7000. L363 
staining of splenic B cells (CD19+), CD8α- or CD8α+ CD11c+ DCs after 20h of coincubation with 200ng/ml 
DB03-4 or KRN7000. 
This difference might be explained by the increased CD1d expression on CD8α+ DCs (Figure 22 
A), as well as their higher lipid raft content, as revealed by the staining with Cholera Toxin B 
(Figure 22 B), as apolar GSLs are reported to be preferentially presented on lipid rafts44. 
 
Figure 22 - A) CD1d and B) Cholera Toxin B staining in APC populations in spleen. 
 
To assess whether a differential affinity of APCs for either DB03-4 or KRN7000 could explain 
the preferential iNKT cell anergy induction by KRN7000, we injected several types of APCs 
pulsed with either DB03-4 or KRN7000 in mice (Figure 23 A).  
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Figure 23 - Different APCs induce similar levels of iNKT cell anergy. A) Schematic representation of the 
experiment: APCs were loaded for 24h with 200ng/ml of either DB03-4 and KRN7000, washed 3 times 
and injected i.v. in mice. Animals were rechallenged 8 days later. B) and C) Intracellular cytokine 
staining of ex vivo splenic iNKT cells restimulated in vivo with 1μg of KRN7000 for 3h and ex vivo-
cultured for 4h with Brefeldin A and Monensin.     
Mice were rechallenged one week later to monitor the anergy in iNKT cells. Surprisingly, B 
cells and splenic DCs, as well as the CD8α+ DC cell line 1940238, or the T cell lymphoma EL4-
CD1d, transduced to express high levels of CD1d (Figure 24), similarly induced iNKT cell anergy 
when loaded with KRN7000, but not with DB03-4 (Figure 23 B). Furthermore, IL-10 production 
was increased in iNKT cells when anergized with KRN7000-pulsed DCs (Figure 23 C). These 
results show that the phenomenon of anergy induction is not related to the nature of the APC 
and that any APC has the ability to induce it. 
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Figure 24 - CD1d expression level in EL4 and EL4 transduced with mouse CD1d. 
I.3.4 Fixation of DCs pulsed with DB03-4 sustains its presentation 
A study by the group of Porcelli reported that surface-loaded Th2-biasing glycolipids, which 
are more polar, are not stably presented on the surface of APCs because they are quickly 
unloaded in acidic endosomes during the recycling of CD1d45. To assess that in our system we 
blocked CD1d recycling via PFA fixation of DB03-4-loaded DCs (Figure 25 A). Indeed, we 
showed that, while live DCs quickly lost the presentation of DB03-4 upon withdrawal of the 
GSL from the media, PFA fixation allowed the retention of DB03-4-loaded CD1d molecules at 
the cell surface (Figure 25 B). 
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Figure 25 – Fixation allows the retention of DB03-4 at the surface of DCs. A) Schematic representation 
of the experiment: live or fixed DCs were pulsed for 20h with 200ng/ml of DB03-4 and then washed. 
24h later, the presentation of DB03-4 was assessed by flow cytometry using the L363 antibody. B) L363 
staining of live or PFA-fixed splenic DCs loaded with 200ng/ml DB03-4 for 15h and washed. 
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I.3.5 Sustained presentation of DB03-4 is not sufficient to induce iNKT cell anergy.  
 
Figure 26 – Retention of DB03-4-loaded CD1d at the surface of DCs with PFA fixation is not sufficient 
to induce iNKT cell anergy. A) Schematic representation of the experiment: live or PFA-fixed splenic 
DCs were loaded with DB03-4 or KRN7000, washed and transferred into mice hosts i.v. Mice were 
rechallenged 8 days later with 1μg DB03-4 i.v. to assess for iNKT cell anergy.  B) Intracellular cytokine 
staining of ex vivo splenic iNKT cells restimulated in vivo with 1μg of DB03-4 for 3h and ex vivo-cultured 
for 4h with Brefeldin A and Monensin. 
To assess whether the short presentation of DB03-4 was the reason why this GSL induces less 
iNKT cell anergy than KRN7000, we pulsed live or PFA-fixed splenic DCs with DB03-4 or 
KRN7000 and injected these cells into C57BL/6 hosts (Figure 26 A). Anergy was assessed one 
week later via a restimulation with DB03-4, as described earlier. Interestingly, mice that 
received fixed APCs loaded with DB03-4 did not display more iNKT cell anergy than the animals 
that received live DCs loaded with DB03-4 (Figure 26 B). We also confirmed that fixed APCs 
were able to induce iNKT cell anergy by injecting in mice fixed KRN7000-loaded DCs, which 
induced iNKT cell hyporesponsiveness similarly to live DCs loaded with KRN7000 (data not 
shown). 
These results show that prolonged presentation of the polar GSL DB03-4 via fixation does not 
induce more anergy in iNKT cells.   
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I.3.6 High presentation of DB03-4 is not sufficient to induce iNKT cell anergy 
To fully exclude that saturating and/or sustained GSL presentation to iNKT cells mediates iNKT 
cell anergy, we compared two cell lines as APCs: EL4-CD1d pulsed with DB03-4 presented 200x 
more DB03-4 than 1940 DCs, due to their much higher CD1d expression (Figure 21). This 
presentation was still very high when EL4-CD1d were fixed, which allowed a stable 
presentation over time, as shown before. Similarly, EL4-CD1d had a higher surface 
presentation of KRN7000 than 1940 DCs (Figure 27 B). Mice were then challenged twice with 
APCs fixed or alive and loaded with DB03-4 or KRN7000 (Figure 27 A). Interestingly, EL4-CD1d 
which presented very high amounts of DB03-4 at their surface, did not induce iNKT cell anergy, 
whether live or stabilized with fixation. Furthermore, 1940 DCs which presented much lower 
amount of KRN7000 presentation, significantly induced iNKT cells anergy. These results 
demonstrate that the induction of iNKT cell anergy does not depend on the amount or the 
duration of the antigen presentation, but may rely on the processing of the glycolipid which 
depends on its solubility. 
 
 
Figure 27 – High and sustained DB03-4 presentation is not sufficient to induce iNKT cell anergy. A) 
Schematic representation of the experiment: 1940 and EL4-CD1d cell lines were fixed and pulsed with 
either DB03-4 or KRN7000. These cells were injected on day 0 and 6. Mice were restimulated on day 
12 with KRN7000 to assess for iNKT cell anergy. B) L363 staining of the different GSL-loaded APCs 
before transfer in mice. C) Intracellular cytokine staining of ex vivo splenic iNKT cells restimulated in 
vivo with 1μg of KRN7000 for 3h and ex vivo-cultured for 4h with Brefeldin A and Monensin.   
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I.3.7 iNKT cell anergy induction by KRN7000 does not rely on a mechanism induced by the 
processing of the glycolipid in APCs. 
Apolar glycolipids, which polarize the iNKT cell response towards Th144 and induce iNKT cell 
anergy (Figure 20), require intracellular processing in APCs to be loaded on CD1d44–46. We 
hypothesized that the intracellular antigen processing might participate to the anergy 
induction of iNKT cells. To test this, we loaded EL4-CD1d with DB03-4 or KRN7000 for a very 
short period of time (1.5h) before fixation with PFA. We hypothesized that the short 
incubation time would not allow antigen processing but only surface loading, which would be 
frozen by subsequent PFA fixation. Different doses of GSLs were used to allow a similar surface 
loading of DB03-4 and KRN7000, in view of their different solubility (Figure 28 A). As a control, 
live cells were also loaded with the same high amount of DB03-4 or KRN7000 for different 
durations. Pulsed EL4-CD1d cells were fixed or not and injected in mice. Anergy was assessed 
8 days later by rechallenging mice with 1μg KRN7000 i.v (Figure 28 B). The results showed that 
EL4-CD1d fixed after being loaded with KRN7000 for a short period of time induced similar 
levels of iNKT cell anergy than EL4-CD1d loaded for 8h with KRN7000 and kept alive (Figure 28 
C). These results suggest that the intracellular processing of apolar GSLs is unlikely to be 
responsible for iNKT cell anergy.  
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Figure 28 - iNKT cell anergy induction by KRN7000 does not seem to rely on a mechanism induced by 
the processing of the glycolipid in APCs. A) GSL presentation of EL4-CD1d loaded with KRN7000 or 
DB03-4 with or without fixation post antigen-pulsing. B) Scheme of the in vivo experiment: Live or fixed 
GSL-pulsed EL4-CD1d were transferred i.v. into recipient C57BL/6 hosts. C) Mice were re-challenged 8 
days later with KRN7000 to assess for iNKT anergy. iNKT cell anergy is reported as intracellular 
accumulation of IFN-γ and TNF-α in iNKT cells. 
I.3.8 KRN7000 is a more potent inducer of DC maturation than DB03-4 in vivo 
We finally asked whether DB03-4 was as potent as KRN7000 analog for the maturation of pro-
inflammatory mature DCs and the priming of T cells. To do so, we injected 1μg of either DB03-
4 or KRN7000 in Flt3L transgenic mice, which have higher numbers of DCs in the spleen234. 
Spleens were collected 20h later and DCs maturation was analysed by flow cytometry (Figure 
29 A). DCs from mice treated with KRN7000 up-regulated significantly more CD80 and CD86 
than with DB03-4 (Figure 29 B), indicating their better transactivation as compared to DB03-4 
injection.  
To assess if the superior DC transactivation by KRN7000 over DB03-4 also resulted in a better 
T cell priming, we transferred OT-1 T cells in C57BL/6 mice and vaccinated them 5 hours later 
with the transfer of bone marrow-derived DCs pulsed with the OVA SIINFEKL peptide and 
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DB03-4 or KRN7000. OT-1 expansion was analysed 7 day later in the spleens (Figure 29 C). As 
for DC maturation, KRN7000 induced significantly more OT-1 expansion than DB03-4 (Figure 
29 D). These results show that KRN7000 is more potent than DB03-4 at priming T cell 
immunity, despite the fact that it induces more iNKT cell anergy. 
 
 
 
Figure 29 - DB03-4 is weaker than KRN7000 at maturing DCs and promoting T cell immunity. A) Scheme 
of the experiment: Flt3L mice received 1 μg of DB03-4 or KRN7000 i.v. Splenic DCs were collected and 
analysed 20h later.  B) CD80 and CD86 expression in spleen DCs harvested 20h after GSL injection. C) 
Scheme of the experiment: DCs were differentiated from HSC for 6 days with GM-CSF and IL-4. They 
were then loaded with the SIINFEKL OVA peptide (10 μg/ml) and DB03-4 or KRN7000 (200ng/ml) for 
20h. 0.5x105 CD45.1 OT-1 T cells were injected in recipient CD45.2 C57BL/6 mice, followed by the DCs. 
OT-1 expansion was assessed 7 days later in the spleen.  D) Percentage of spleen OT-1 T cells 7 days 
after vaccination. 
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I.4 Discussion 
In this project, we aimed at comparing the capacity of αGalCer analogs at inducing iNKT cell 
anergy with regard to their hydrophobicity and capacity to induce a Th1/Th2 bias. Based on 
their respective characteristics, we tried to identify a possible cellular mechanism on the APC, 
which may control the induction of anergy in iNKT cells. 
We mainly focused on KRN7000 and DB03-4, as representative Th1 and Th2 analogs.  We first 
confirmed that KRN7000 mainly required internalization by APCs for its efficient CD1d 
presentation via the endosomal pathway, which translated in a slow kinetic. In contrast, the 
more polar Th2 analog DB03-4 quickly loaded on the cell surface of the APCs44. The slow versus 
fast kinetic of CD1d presentation of Th1 versus Th2 analogs also correlated with the delayed 
versus fast iNKT cell activation, and more strikingly with the differential capacity of these GSLs 
to induce iNKT cell anergy.  Indeed, testing a larger panel of Th1 and Th2-biasing αGalCer 
analogs, we demonstrated that  Th1 αGalCer analogs are more potent to induce iNKT cell 
anergy, which was simultaneously shown by the group of Kronenberg54. 
In view of these observations, we investigated whether there was a link between anergy and 
antigen processing by the APC. Several hypotheses have been proposed to explain iNKT cell 
anergy, such as the type of APCs, PD-1 up-regulation or excess of co-stimulation50–54. 
Surprisingly, we found that any APC, even a lymphoma cell line transduced with CD1d, could 
induce iNKT cell anergy to the same extent provided they were loaded with a Th1-biasing 
αGalCer analog.  
The nature of the APC was also proposed to be a mechanism explaining how different αGalCer 
analogs induce either a Th1 or Th2 iNKT response. We indeed found that the Th1-biasing GSL 
KRN7000 loaded preferentially on CD8α DCs, while DB03-4 loaded more on B cells and CD8α- 
DCs. This might be explained by the high density of lipid rafts in CD8α DCs, which quickly 
recruit glycolipid micelles44,48. CD8α DCs were proposed as the main APCs for iNKT cells, which 
also probably results from their higher expression of CD1d, as compared to other DCs and B 
cells. However, we show that independently of the presence of rafts, or level of CD1d 
expression, any APC is able to induce anergy in iNKT cell, when loaded with an apolar GSL. 
Similarly, Wingender et al. recently showed that neither B cells or DCs are required for the 
anergy induction of iNKT cells54. Collectively, data from the literature and our results 
demonstrate that the selective loading of GSLs on different APCs is not the main mechanism 
involved in the Th1/Th2 bias or the onset of anergy in iNKT cells. 
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We then asked whether the sustained presentation of Th1 GSLs was required for the onset of 
iNKT cell anergy. Indeed, we showed that the Th1-biasing αGalCer analog is stably presented 
on CD1d in contrast to the Th2-biasing GSL DB03-4. The mechanism accounting for this 
differential presentation has been elucidated by Porcelli et al44,45, by showing that polar Th2-
biasing GSLs mainly load on the cell surface and quickly unload from CD1d in acidic endosomes 
during the dynamic CD1d turnover. We observed that the fixation of APCs presenting DB03-4 
allowed the stabilisation over time of CD1d/DB03-4 complexes, mimicking the stable 
presentation of Th1 GSLs. However, fixed DB03-4-pulsed DCs did not induce more iNKT cell 
anergy than their live counterparts. Even when using EL4 T cell lymphoma transduced to 
express very high level of CD1d, both live and fixed EL4-CD1d loaded with DB03-4 failed to 
induce iNKT cell anergy. These data strongly suggest that the strength and duration of GSL 
presentation is not a prerequisite for the induction of iNKT cell anergy. 
Porcelli et al. showed that neutralization of endosome acidification with chloroquine or NH4Cl 
increased the localization of CD1d/Th2 GSLs to lipid rafts, as CD1d molecules trafficking from 
endosomes towards membrane lipid rafts were able to keep Th2 GSLs loaded. Furthermore, 
chloroquine-treated APCs loaded with Th2 GSLs induced some features of Th1 GSLs in vivo46. 
Unfortunately, we were not able to confirm those results of DB03-4 presentation on raft 
domains in APCs when treated with chloroquine (data not shown). Instead, we showed that 
loading for a short period of time of 90 min high amounts of KRN7000 mainly allowed its 
surface loading without preferential enrichment on raft domains. Interestingly, we found out 
that surface-loaded KRN7000 still induces iNKT cell anergy, which suggests that preferential 
localization of CD1d/GSL complexes in raft domains is not a prerequisite for anergy induction 
in iNKT cells. Furthermore, the short pulsing of KRN7000 immediately followed by cell fixation 
likely exclude that phenotypical changes in APCs are not required for iNKT cell anergy 
induction. Such a mechanism was proposed to play a role in the capacity of DCs to bias the 
iNKT cell response towards Th1 or Th2 when loaded with apolar or polar GSLs, respectively. 
Apolar GSLs were described to induce CD86 and Rae-1 on DCs, while their polar analogs 
induced PD-L1 and PD-L248. We were however not able to confirm phenotypic changes of DCs 
when loaded with either DB03-4 or KRN7000. 
To conclude, the mechanism underlying the induction of iNKT cell anergy by apolar Th1-
biasing GSLs remains elusive as it does not involve a specific APC population, nor a long 
duration or strength of presentation, nor enriched presentation in rafts or phenotypical 
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differences in APCs. The difference between apolar and polar GSLs may reside in their nature, 
as apolar GSLs have a longer hydrophobic tail. Indeed, crystallographic analysis showed that 
the acyl chain of αGalCer fully fills the A’ pocket of human CD1d, which induces a 
conformational change in CD1d, when compared with the unloaded molecule10. Polar GSLs 
have generally smaller acyl tails or insaturations, which decrease their affinity for CD1d and 
might induce weaker or different conformational changes on CD1d, which would then be seen 
differently by the semi-invariant TCR and induce a different outcome in iNKT cells. 
Importantly, we showed that, while Th1 αGalCer analog KRN7000 induces iNKT cell anergy, it 
is also a much better adjuvant for DC maturation and T cell priming than Th2-biasing DB03-4, 
which induces less anergy. Therefore, for vaccine development, the Th1-biasing αGalCer 
analogs are much preferred and actively tested in pre-clinical239–241 and clinical studies191,192. 
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J PD1 blockade combines with the iNKT cell activation to enhance the 
CD8 T cell-mediated anti-tumoral response 
J.1 Aim 
The aim of this project was to find a way to improve the adjuvant effect of αGalCer on adaptive 
immunity shown by us and others55,56,65–69,188. DC vaccines involving the ex vivo maturation 
and antigen pulsing of pro-inflammatory DCs have reached clinical usage170,242–244, and also 
showed promising cell responses in conjunction with iNKT/CD1d ligands187,192,245. In this 
project, we combined a DC/αGalCer vaccine with PD1 blockade and hypothesized that the two 
treatments would synergistically enhance T cell-mediated tumor rejection. Indeed, on one 
hand the crosstalk between iNKT cells and DCs would promote a potent T cell priming, while 
PD-1 blockade would restore the effector functions of the primed T cells within the tumor 
micro-environment. 
J.2 Material and methods 
J.2.1 Tumor engraftment 
B16F10 or MC-38 tumors were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco 
10566-016) with 10% FCS, 50U/ml Penicillin-Streptomycin, 50μM β-mercapto-ethanol and 
100mM HEPES. Prior to engraftment, cells were detached with PBS 5mM EDTA, washed 3 
times with ice-cold PBS. 105 B16F10 or 7x105 MC-38 were then resuspended in 200μl cold PBS 
and engrafted s.c. on the flank of C57BL/6 mice with a 25G syringe needle (Braun, 041-
921019). 
J.2.2 Subcutaneous peptide vaccination 
The vaccination was prepared with 10μg Trp2180-188 (SVYDFFVWL) and 50μg poly(I:C) HMW 
(Invivogen tlrl-pic-5) or 1μg αGalCer (Enzo Life Sciences BML-SL232-1000) diluted in 200μl of 
PBS.  Mice were subcutaneously vaccinated at the base of the tail with a 25G syringe needle. 
J.2.3 Ex vivo DC maturation and loading with Trp2 peptide for vaccination 
DCs were isolated from Flt3L transgenic spleens as described in I.2.2. Splenocytes were 
cultured in IMDM medium supplemented with 10% FCS, 50U/ml Penicillin-Streptomycin 
(Gibco 15070-063), 0.075% Sodium Bicarbonate (Thermo Fisher Scientific 25080094), 10mM 
HEPES (Gibco 15630080), 1x MEM NEAA (Gibco 11140050), 50μM β-mercapto-ethanol (Gibco 
31350010) at the concentration of 2x106 cells/ml in poly-lysine-coated 6 well plates. The 
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medium was supplemented with 5μg/ml poly(I:C) and 10μg/ml of the indicated peptide. After 
20h of culture, cells were detached with cold PBS 5mM EDTA, washed 3 times with PBS. 
Correct maturation and viability were checked by flow cytometry with the CD80-PE 
(BioLegend 104707) and CD86-FITC (BioLegend 105005) antibodies and Fixable Viability Dye 
eFluor 506 (eBioscience 65-0866-14). 2x106 cells were resuspended in 200μl of plain RPMI 
medium and injected i.v. into mice.  
2x106 cells were resuspended in 200μl of plain RPMI medium and injected i.v. into mice.  
J.2.4 DC loading with αGalCer and Trp2 peptide for vaccination 
DCs were isolated and cultured as in J.2.3. The medium was supplemented with 10μg of the 
indicated peptide and 200ng/ml αGalCer. After 20h of culture, cells were washed 3 times with 
cold PBS. Viability and αGalCer loading were checked by flow cytometry with Fixable Viability 
Dye eFluor 506 and the L363-PE antibody.  2x106 cells were resuspended in 200μl of plain 
RPMI medium and injected i.v. into mice.  
J.2.5 Lymphodepletion and Pmel transfer 
One day prior to adoptively transfer hgp100-specific CD8 T cells, mice were irradiated with 
5Gy in a RS2000 X-Ray irradiator (Rad Source). On the next day, hgp100-specific CD8 T cells 
were purified from spleen of Pmel transgenic mice using the EasySep™ Mouse CD8+ T Cell 
Isolation Kit (Stem Cell 19853) according to the manufacturer protocol. The concentration of 
hgp100-specific T cells in the bulk CD8 T cells was determined by flow cytometry and hgp100 
multimer staining. 105 hgp100-specific CD8 T cells were transferred i.v. in plain RPMI medium. 
J.2.6 anti-PD1 therapy 
200μg of anti-PD1 clone RMP1-14 (Bio X Cell BE0146) were diluted in 200μl of PBS and injected 
i.p. in mice using a 26G syringe needle (Terumo 041-050101). 
J.2.7 Tumor dissociation  
Tumors were collected and separated from skin. Single cell suspensions were obtained with 
the Mouse Tumor Dissociation Kit (Miltenyi 130-096-730) according to the manufacturer 
protocol. Single cells were then resuspended in 40% Percoll (36% Percoll [GE Life Sciences 17-
0891-01], 4% 10x PBS, 60% full DMEM medium). 70% Percoll (63% Percoll, 7% 10x PBS, 30% 
full DMEM medium) was carefully poured on top, avoiding the mix of the two phases. 
Afterwards, the tubes were centrifuged at the speed of 950rcf. Finally, the lymphocytes 
accumulating at the interphase were collected and washed in full medium. 
 73 
J.2.8 Ex vivo restimulation of spleen and tumor T cells 
To stain for cytokines, around 0.5 to 1x106 spleen and tumor single cells were plated in flat-
bottom 96well plates with 10μM of the indicated peptides. 30min later, the Monensin and 
Brefeldin A-containing reagents Golgi Stop and Golgi Plug (Beckton Dickinson 554724 and 
555029) were added at the final concentration of 1:1000. Cells were further incubated for 4h 
prior to staining for flow cytometry. 
J.2.9 Flow cytometry staining of spleen and tumor T cells 
Cells were washed with FACS buffer (PBS, 2% FCS and 2.5mM EDTA) and incubated for 15min 
with 2.4G2 supernatant to block the Fc receptors CD16 and CD32233. Next, cells were stained 
with Fixable Viability Dye eFluor 506 according to the manufacturer protocol. 
Consecutively, the cells were stained with the indicated PE-labelled MHC-I/peptide multimers. 
The cells were then surface-labelled with the antibodies CD3ε-Alexa Fluor 700 at 10μg/ml 
(BioLegend 100215), CD8α-Brilliant Violet 650 at 0.5μg/ml (BioLegend 100741), PD1-APC at 
1μg/ml (BioLegend 135209), CD44-APC/eFluor 780 at 2μg/ml (eBioScience 47-0441-82) and 
CD62L-PE/Cy7 at 0.5μg/ml (BioLegend 104417). 
To stain for intracellular cytokines, cells were fixed using a fixation buffer for intracellular 
stainings (Biolegend 420801) according to the manufacturer protocol, before being stained 
with the antibodies IFNγ-PerCP/Cy5.5 at 0.5μg/ml (Biolegend 505821), TNFα-Pacific Blue at 
1μg/ml (Biolegend 506318) and Granzyme B-PE/Texas Red at 1:200 (according to the 
indications of the manufacturer, Thermo Fischer Scientific GRB17) diluted in permeabilization 
buffer (Biolegend 421002) for 30min on ice. Cells were finally washed twice in permabilization 
buffer and resuspended in FACS buffer prior to acquisition.    
CD4 T cells were stained with the CD4-PerCP/Cy5.5 antibody (BioLegend 100433) at 0.5 μg/ml. 
The cells were permeabilised for nuclear staining using the Foxp3 / Transcription Factor 
Staining Buffer Set (eBioscience 00-5523-00) according to the manufacturer protocol. 
Afterwards, cells were stained with FoxP3-Alexa Fluor 488 at 2.5μg/ml (BioLegend 126405) 
and T-bet-APC at 1μg/ml (BioLegend 644813) in FoxP3 permeabilization buffer (perm buffer) 
(eBioscience 00-5523-00). Cells were finally washed twice in FoxP3 perm buffer and finally 
resuspended in facs buffer prior to analysis on a Beckton Dickinson LSRFortessa flow 
cytometer. 
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J.3 Results 
J.3.1.1 αGalCer-pulsed DCs are superior to poly(I:C) for CD8 T cell priming 
In order to illustrate the advantage of using αGalCer as an adjuvant for cancer vaccines, we 
compared it with the TLR3 agonist poly(I:C). To do so, we engrafted B16F10 tumors in mice 
and vaccinated them with the Trp2180-188 peptide, which is a tumor-associated antigen in B16 
melanoma246. We tested different vaccination strategies: s.c. immunization with Trp2 and 
poly(I:C), as previously described by our group247, or with Trp2 and αGalCer. In addition to s.c. 
peptide immunization, we also compared DC vaccine, either loaded with the Trp2 peptide and 
αGalCer, or DCs matured ex vivo with poly(I:C) and loaded with Trp2 (Figure 30 A). DCs viability 
and loading with αGalCer was verified by flow cytometry before transfer. The maturation 
status of ex vivo DCs matured with poly(I:C) was confirmed by the upregulation of CD80 and 
CD86 (Figure 30 B). The efficacy of the vaccination strategies was tested 7 days later by 
comparing the percentage of H2-Kb/Trp2180-188-specific CD8 T cells in the blood (Figure 30 C). 
Both groups of mice vaccinated s.c. with the peptide and αGalCer or poly(I:C) had very low 
levels of peripheral Trp2-specific CD8 T cells, in view of the low frequency of Trp2-specific T 
cell precursors. The expansion of Trp2-specific T cells remained quite low for poly(I:C)-
matured DCs loaded with Trp2 peptide. In contrast, ex vivo DCs loaded with both the Trp2 
peptide and αGalCer induced significantly more Trp2-specific T cells than all the other groups. 
These mice also displayed the best tumor control, although differences were not statistically 
significant (Figure 30 C).  
These data show that DCs loaded with both αGalCer and a peptide antigen are very potent at 
inducing an endogenous antigen-specific CD8 T cell response. 
 
 75 
 
Figure 30 - Better CD8 T cell priming with transferred DCs loaded with αGalCer than matured with 
poly(I:C). A) Scheme of the experiment: 105 B16F10 tumors were engrafted s.c. in the flank of C57BL/6 
mice. One week later, mice were vaccinated with either DCs matured with poly(I:C) and loaded with 
the Trp2180-188 peptide, or DCs loaded with αGalCer and Trp2 peptide or with s.c. injection of Trp2180-
188 peptide and poly(I:C) or αGalCer. B) Viability and L363 staining of the DCs loaded with αGalCer prior 
to injection (left) and viability and CD80 and CD86 staining of DCs matured with poly(I:C) (right). C) H2-
Kb/ Trp2180-188 multimer staining of blood CD8 T cells 7 days after vaccination. D) Kinetic of tumor 
growth. 
J.3.2 Adoptive T cell transfer and DC/αGalCer vaccine strongly rejects established tumors 
In the Trp2 model, vaccination expanded the endogenous pre-existing Trp2-sepcific T cells. 
We then investigated how DCs loaded with αGalCer with or without peptide would expand a 
pool of transferred tumor-specific CD8 T cells. To do so, we engrafted B16F10 in C57BL/6 mice. 
To favour the engraftment of adoptively-transferred T cells248, we lymphodepleted the hosts 
by X-ray irradiation of 5Gy on day 8. On day 9, we transferred 105 H2-Kb restricted Pmel T cells 
specific for the human gp100 melanoma TAA, which also crossreact the murine gp100 epitope 
expressed in B16F10 tumors249. On the next day, mice were vaccinated with 2x106 DCs loaded 
with αGalCer with or without the human gp10025-33 peptide, as the murine ortholog is not 
immunogenic in mice249 (Figure 31 A). Interestingly, the vaccination with αGalCer-pulsed DCs 
in the absence of gp100 peptide already induced a very strong tumor control, significantly 
better than the non-vaccinated group, which also received tumor-specific Pmel T cells. These 
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results suggest that the αGalCer/DCs were able to prime Pmel T cells against the B16 tumors. 
Most importantly, the vaccination with DCs loaded with both αGalCer and hgp10025-33 was 
even more potent, as it induced almost complete tumor rejection (Figure 31 B). In line with 
this tumor inhibition, we observed that Pmel T cells were significantly enriched in the spleen 
and tumors of mice vaccinated with both αGalCer and peptide-pulsed DCs. Additionally, a 
higher proportion of Pmel had an effector phenotype in the spleen of mice treated with the 
combined vaccination (Figure 31 C). Finally, mice in this group presented a higher Pmel/Treg 
ratio in both the spleen and tumors, which is generally associated with successful tumor 
control247. Collectively, these data show that DC/αGalCer enhance the tumor control by 
priming and expanding adoptively transferred tumor-specific T cells. However, this effect can 
be greatly potentiated by adding a tumor peptide antigen to the vaccine.  
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Figure 31 - Adoptive T cell transfer and DC/αGalCer vaccination induces a strong antitumor T cell 
immunity. A) Scheme of the experiment: 105 B16F10 tumors were engrafted. On day 8, mice were 
lymphodepleted with a single dose of 5Gy X-ray. 105 Pmel CD8 T cells were injected i.v. on day 9.  The 
mice were then vaccinated on day 10 and rechallenged with 1μg of αGalCer on day 14. B) Tumor 
growth kinetics. C) Spleens and tumors were collected on day 24 and cells were analysed by flow 
cytometry. 
J.3.3 Antitumor additive effect between DC/aGC/Trp2 vaccine and PD-1  
To investigate whether the immunotherapeutic effect of DCs loaded with αGalCer could be 
further improved, we tried to combine it with the checkpoint blockade anti-PD1. Indeed, as 
we observed that our DC/αGalCer vaccine was able to prime efficiently CD8 T cells, we 
hypothesized that anti-PD1 therapy would further support those T cells in the tumor 
microenvironment. Therefore, we checked whether the potent antitumor effect generated by 
the aGC/Trp2/DC vaccine could be further enhanced by PD-1 blockade. Mice were engrafted 
with B16F10 tumors and vaccinated one week later with DCs loaded with αGalCer +/- Trp2180-
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188 peptide. Mice were treated twice with anti-PD1 one week later, at 3 days interval (Figure 
32 A). In the absence of the Trp2 peptide, DC/αGalCer treatment reduced the tumor burden 
compared to the control group, although not significant. Moreover, the addition of anti-PD1 
to DC/αGalCer did not improve the control of the tumors, suggesting that T cell priming by the 
B16 tumor was too weak. However, when the Trp2 peptide was added to the DC/αGalCer 
vaccine, the control of the B16 melanoma tumors was significantly improved. Most 
importantly, the addition of anti-PD1 further improved the tumor control in the 
DC/αGalCer/Trp2 group (Figure 32 B), although not statistically significant. In line with these 
therapeutic results, we saw a higher frequency of H2-Kb/Trp2180-188-specific CD8 T cells in the 
spleen of DC/αGalCer/Trp2 + anti-PD1 treated mice (Figure 32 C), which was however not 
confirmed in the tumors (Figure 32 D). Nevertheless, after restimulation with the Trp2 
peptide, we saw that tumor isolated Trp2-specific T cells from the DC/αGalCer/Trp2 + anti-
PD1 group significantly expressed more Granzyme B and secreted more IFNγ and TNFα than 
the other groups. 
Collectively, these data show that DC/αGalCer/peptide vaccination is enhanced by the anti-
PD1 treatment in the B16 model by promoting on one hand a better priming and on the other 
hand improved effector functions at the tumor site.  
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Figure 32 - DC/αGalCer/Trp2 vaccination is enhanced by anti-PD1 treatment against B16 melanoma 
tumors. A) Scheme of the experiment: 105 B16F10 tumors were engrafted in C57BL/6 mice. The 
animals were vaccinated one week later with DCs loaded with αGalCer +/- Trp2180-188 peptide. Mice 
were treated with 200μg of anti-PD1 i.p. on days 13 and 17. Animals were sacrificed on day 22. B) 
Tumor growth kinetic and tumor volumes on day 20. C) Ex vivo staining of H2-Kb/Trp2180-188-specific 
CD8 T cells in the spleen and D) in the tumor. D) Intracellular cytokine staining of tumor Trp2-specific 
T cells restimulated with the Trp2180-188 peptide.    
J.3.4 The control of established MC-38 tumors by DC/αGalCer vaccination is improved when 
combined with anti-PD1 
We then checked whether our DC/αGalCer + anti-PD1 treatment without peptide was 
sufficient to induce an antitumor response in a tumor model that is more immunogenic than 
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B16. Therefore, we engrafted mice with the MC-38 colon adenocarcinoma cell line and 
vaccinated the mice one week later. On the next day, mice were treated with anti-PD1 3x at 3 
days of interval (Figure 33 A). Mice treated with DC/αGalCer or unloaded DCs with anti-PD1 
similarly controlled the growth of MC-38 tumors. However, DC/αGalCer and anti-PD1 induced 
a better control of MC-38 tumors, when combined (Figure 33 B).  
These data show that anti-PD1 significantly enhances the antitumor immune response driven 
by the vaccination with DCs loaded with αGalCer. However, we were not able to track the 
tumor-specific CD8 T cell response in these mice. 
 
Figure 33 - DC/αGalCer vaccination controls better established MC-38 tumors when combined with 
anti-PD1. A) Scheme of the experiment: 7x105 MC-38 tumors were engrafted s.c. Mice were vaccinated 
on day 7 and received 3 anti-PD1 doses of 200μg i.p. on days 8, 11 and 14. The mice were rechallenged 
with 1μg of free αGalCer i.v. on day 14. B) Tumor growth.   
J.3.5 DC/αGalCer vaccination increases the functionality of neoantigens-specific CD8 T cells 
in the MC38 tumor model 
With the aim to identify the tumor antigens which raised the potent CD8 T cell response in 
the MC38 model, we tested some neo-antigens that were recently described for this tumor. 
The first one is a single amino acid substitution in the Adpgk gene, the ADP-specific 
glucokinase, which generates a neoantigen250.  
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Figure 34 –Neoantigens predicted in the MC-38 model. Adapted from 250. 
The second one is a peptide derived by the gp70 retroviral gene expressed in several mouse 
tumor cell lines including MC-38 251,252. Mice bearing MC-38 tumors were vaccinated with 
DC/αGalCer +/- Adpgk neoantigen peptide. The animals were treated subsequently with anti-
PD1 (Figure 35 A). As in previous experiments, we saw that DC/αGalCer and anti-PD1 
significantly work together to control the tumor burden. However, the antitumor effect was 
not improved by the addition of the Adpgk neoantigen peptide on DCs (Figure 35 B). 
Surprisingly, although DC/αGalCer/Adpgk + anti-PD1 did not enhance the tumor control, it 
clearly induced H2-Db/Adpgk-specific CD8 T cells in seen in the spleen (Figure 35 C). However, 
Adpgk-specific CD8 T cells were not detected in the absence of the adpgk peptide in the DC 
vaccine although it induced the same effective tumor control in the group DC/αGalCer + anti-
PD1, suggesting that other tumor antigens may be seen. In the tumor, neither of the two 
groups displayed a consistent enhanced frequency of Adpgk-specific CD8 T cells. However, 
upon ex vivo restimulation of TILs with the Adpgk peptide, these two groups displayed high 
Granzyme B expression and IFNγ secretion in CD8 T cells, suggesting that the adpgk 
neoantigen may participate to the CD8 T cell mediated tumor control (Figure 35 C).  
DC/αGalCer + anti-PD1-treated mice, which displayed the best tumor control did not 
accumulate H2-Kb/gp70-specific CD8 T cells in spleen or tumor (Figure 35 D). However, 
similarly to Adpgk, the restimulation with the gp70 peptide revealed an increased Granzyme 
B expression and IFNγ secretion in tumor CD8 T cells, suggesting that this viral antigen may 
also participate to the tumor control. 
Collectively, these results suggest that multiple tumor antigens likely participate to the 
immune response against the MC38 tumors, which raises the possibility to pulse DC/αGalCer 
with a pool of peptides in order to increased efficacy of DC/αGalCer vaccines.  
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Figure 35 - DC/αGalCer vaccination increases the functionality of neoantigens-specific CD8 T cells in 
the MC38 tumor model. A) Scheme of the experimental plan: 7x105 MC38 tumors were engrafted in 
C57BL/6 mice. Animals were vaccinated 4 days later with DC/αGalCer +/- Adpgk peptide. Animals were 
treated twice with anti-PD1 on days 5 and 8 and were sacrificed on day 11. B) Tumor growth and 
volume at day 11. C) and D) Frequency in spleen and tumors and ex vivo restimulation of TILs seen by 
intracellular cytokine stainings with regard to Adpgk and gp70-specific CD8 T cells, respectively. 
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J.4 Discussion 
As shown by other studies253,254, we confirmed the potency of DC vaccines, as compared to 
conventional formulation of peptide/adjuvant247. Furthermore, we demonstrated that pulsing 
immature DCs with αGalCer instead of inducing their in vitro maturation with poly(I:C) 
resulted in much better CD8 T cell priming. The major reason is that TLR-mediated activation 
of DCs make them prone to apoptosis rapidly after their maturation255, resulting in their poor 
survival after in vivo transfer. In contrast, immature DCs pulsed with αGalCer will proceed to 
their maturation only  upon their encounter with iNKT cells66–69 after their in vivo transfer.  As 
a consequence, αGalCer-loaded immature DCs will likely survive better and thus have a 
prolonged interaction with T cells, which would result in a better T cell priming. 
αGalCer and its Th1-biasing derivatives are potent adjuvants11,239,241,256, which allows the 
transactivation of DCs and efficient T cell priming before iNKT cells become unresponsive. 
Therefore, in the context of therapeutic cancer vaccine, consecutive iNKT cell anergy is not a 
major issue, since their helper T cell function is exploited. In order to further optimize the 
functionality of CD8 T cells primed by αGalCer/DC vaccination, we included PD-1 checkpoint 
blockade, with the hypothesis that these two modalities would synergize as they function at 
different steps of the cancer-immunity cycle, proposed by Chen and Mellman to mount a 
successful antitumor T cell-mediated immunity151. 
To this aim, we tested αGalCer/DC vaccination involving two different tumor antigens in the 
poorly immunogenic and aggressive B16 melanoma model, including the ACT of T cell 
precursors. Briefly, DC loaded with αGalCer and with and without hgp100 peptide epitope was 
performed with prior ACT of hgp100-specific Pmel CD8 T cells. The transfer of Pmel T cell 
precursors was optimised by prior X-ray irradiation, which played an important role in their 
efficient antigen priming and resulted in the almost complete rejection of established B16 
melanomas, especially when the hgp100 peptide was added to the DC/αGalCer vaccine.  
Several clinical trials have taken advantage of TILs as tumor-specific T cells to treat cancer 
patients when adoptively transferred after an ex vivo expansion process211–215. Our data 
indicate that DCs loaded with αGalCer could potentially be beneficial in combination with 
adoptive TILs transfer to further improve their therapeutic effect. Alternatively, DC/αGalCer 
could be loaded with oxidized tumor lysates182,257, which could boost an existing antitumor 
response in cancer patients. As TILs are generally exhausted258, they might benefit from the 
strong pro-inflammatory phenotype of DC/αGalCer after their in vivo encounter with iNKT 
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cells. In this model, we were however unable to show synergy between DC/αGalCer vaccine 
and checkpoint blockade (data not shown), which might have resulted from the already 
maximized efficacy. 
Since adoptive T cell transfer in cancer patients requires heavy and costly infrastructures and 
handling, we tested the melanoma-specific model antigen Trp2 which is able to raise an 
endogenous T cell response resulting in significant tumor inhibition247. The detection of Trp2-
specific T cells in spleen and tumors, as well as the resulting tumor inhibition, were greatly 
increased by the addition of the Trp2 peptide in the αGalCer/DC vaccine formulation. 
However, the addition of PD-1 blockade only slightly improved the therapeutic effect. At the 
cellular level, PD-1 blockade did not improve the frequency of Trp2-specific T cells at the tumor 
and only slightly improved their functionality. This lack of synergy with PD-1 blockade likely 
result from the  low MHC I expression and low immunogenicity of the B16 melanoma model259 
as well as to the poor delivery of tumor antigens to the lymph nodes in this model, which is 
required for antitumor immunity260–262. Similar observations have been made in clinical 
settings showing high tumoral MHC-I expression, a pre-existing T cell response and a high 
mutational load correlate with improved response rate to PD1 checkpoint blockade263–269. 
To address this aspect of tumor immunogenicity, we tested the tumor model of the colon 
carcinoma-derived MC38 cell line, which expresses about ten times higher MHC I levels. 
Strikingly, there was a strongly improved tumor control when combining DC/αGalCer and anti-
PD1 treatment even in the absence of any added tumor antigen, suggesting a strong T cell 
priming by antigens released by the tumor itself.  
With the aim to identify the antigen specificity of the T cell response against MC38 tumors, 
we tested the neoantigen epitope Adpgk, described to be immunogenic in a screening study 
combining in silico prediction and peptide elution from MHC to discover new epitopes in the 
MC38 tumor model250. Despite the detection of increased Adpgk-tetramer specific CD8 T cells 
in the spleen of mice vaccinated with DC/αGalCer/Adpgk and treated with anti-PD1, the tumor 
control was not better than in mice treated with DC/αGalCer + anti-PD1. These results suggest 
that additional MC38-derived antigens participate to the T cell response induced by 
DC/αGalCer vaccination. However, recent identification of personalized neoantigens-derived 
peptides will offer a new effective vaccine approach in cancer patients, especially when 
combined with anti-PD1181.  
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Altogether, these results show that depending on the tumor model, the addition of peptide 
to the DC/αGalCer vaccination and combined with anti-PD1 treatment, may increase or not 
the efficacy of the treatment. The reasons behind this difference are still elusive.  
Collectively, we show for the first time that DC/αGalCer vaccination may be strongly benefit 
from anti-PD1 immunotherapy, especially against immunogenic tumors.  
Furthermore, we aim at challenging our immunotherapeutic combo with a melanoma model 
that recapitulates the biology of human melanoma such as the YUMM1.7 line270 and unlike 
B16. The carcinogenesis of this cell line is driven by Braf activation, Pten and Cdkn2a 
inactivation. As B16, these tumors are poorly immunogenic. Therefore, we expect to observe 
a cooperative effect of DC/αGalCer + anti-PD1 therapy only when coupled to peptide 
vaccination, as in B16.  
We aim also at testing whether our combo immunotherapy induces antigen spreading. 
Indeed, antigen spreading was shown to happen both in mouse models and clinical studies 
and was generally associated with good prognosis271–275. To test this hypothesis, we plan to 
engraft B16F10 sufficient and deficient for Trp2 on both flanks of the same mice. We would 
then monitor whether vaccination with DC/αGalCer/Trp2 + anti-PD1 induces the control as 
well of the Trp2-deficient tumors. 
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K CAR expression interferes with T cell receptor signalling in vivo in 
CD8 T cells 
K.1 Aim 
The original aim of this project was to combine CAR and TCR activation within the same T cell. 
We initially created a CAR reactive to CD1d/αGalCer based on the L363 antibody237, mimicking 
the semi-invariant iNKT TCR. We hypothesized that the combination of CAR and TCR would 
enhance the in vivo recall to a vaccine containing both antigens which would increase the 
cytotoxicity against tumors expressing CAR and TCR-specific antigens. However, OT-1 CAR T 
cells failed to expand in vivo upon OVA/CpG vaccination. These preliminary results suggested 
that the CAR domains interfered with the TCR signalling upon TCR activation even without 
CAR triggering. Therefore, in this project, we aimed at understanding the mechanisms 
hindered the expansion of CAR CD8 T cells upon TCR stimulation. We found out that in vivo 
TCR stimulation of CAR T cells results in Fas-mediated AICD, which was so far not described 
and which may have crucial implications for further developments of CAR-mediated 
immunotherapy. 
K.2 Material and methods 
K.2.1 Retroviral constructs 
BFP fluorescent protein, HER2 and CEA-specific CARs were cloned in the MSGV retroviral 
transfer vector276 under the control of the 5’ LTR promoter. The plasmid pIG6-4D5, containing 
the scFv fragment derived from the mouse anti-HER2 antibody 4D5, was used as template277 
(kind gift from A. Pluckthun, University of Zurich, Switzerland) for cloning the HER2 binding 
domain of the CAR. For the CEA-CAR, the scFv MFE23278 (kindly provided by R.H. Begent) was 
used. The single chain antibody domains of the CARs were fused to CD8α hinge and 
transmembrane domains followed by intracellular TCR signalling endodomains. 
The miRNAs against Fas were co-expressed with ZsGreen in pLMN expression vectors 
(Transomic, shERWOOD-UltramiR). 
K.2.2 Retrovirus preparation 
For each retroviral preparation, 8x106 Phoenix ECO cells (ATCC, CRL-3214) were plated in a 
T150 tissue culture flask in RPMI medium supplemented with 10% FCS, 10mM HEPES and 
50U/ml Penicillin-Streptomycin. On the next day, cells were transfected with 21µg of the 
retroviral construct and 14µg pCL-Eco with Turbofect transfection reagent (Thermo Fischer 
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Scientific, R0532), according to the manufacturer protocol. pCL-Eco279 was a gift from Inder 
Verma (Addgene, plasmid #12371). The medium was changed daily and collected at 48h and 
72h post transfection. 48h and 72h virus supernatants were pooled and sedimented at 
22000rcf for 2h at 4°C. Finally, retrovirus pellets were resuspended in 2ml of full RPMI medium 
and divided in 8 aliquots of 250μl each, which were snap-frozen on dry ice and stored at -80°C.  
K.2.3 Mouse CD8 T cells transduction 
Spleens from CD45.1xOT1 or CD45.1xP14 transgenic mice were smashed on a 40μm cell 
strainer. CD8 T cells were then purified using the EasySep™ Mouse CD8+ T Cell Isolation Kit 
(StemCell, 19853) according to the manufacturer protocol. 0.5x106 CD8 T cells were plated in 
48well plates in 0.5ml of RPMI 1640 medium containing GlutaMAX (Thermo Fischer Scientific, 
61870-010) and supplemented with 10% FCS, 50U/ml Penicillin-Streptomycin (Gibco, 15070-
063), 10mM HEPES (Gibco, 15630080), 1x MEM NEAA (Gibco, 11140050), 50μM β-mercapto-
ethanol (Gibco, 31350010), 2mM L-Glutamine (Thermo Fischer Scientific, 25030081), 1mM 
Sodium Pyruvate (Gibco, 11360070), and 50 IU/ml of recombinant human IL-2. Finally, Mouse 
T-Activator CD3/CD28 Dynabeads for T-Cell Expansion and Activation (Gibco, 11452D) were 
added at a ratio of 2 beads per cell. Retroviral infection was conducted at 37°C for 24h. 
Non-tissue culture-treated 48well plates were coated for 24h with 20μg/ml of recombinant 
human fibronectin (Takara Clontech, T100A) at 4°C, followed by PBS 2% BSA for 30min at RT 
and finally washed with PBS.  One aliquot of 250μl of concentrated retroviruses were plated 
in each of the fibronectin-coated 48well plates and centrifuged for 90min at 2000rcf and 32°C. 
Then, 0.5x106 of 24h-activated CD8 T cells were added on top of the viruses and spun for 
10min at 400rcf and 32°C. 
The medium was renewed daily, and cell density was kept below 2x106 cells/ml. On day 3, the 
medium was supplemented with 10 IU/ml recombinant human IL-2, 10ng/ml recombinant 
human IL-7 and 10ng/ml recombinant human IL-15. From day 5 post activation, the cells were 
fed with only IL-7 and IL-15. 
 
K.2.4 Listeria-OVA and LCMV infection 
Listeria-OVA N4 and T4 were generated as described in 280. 2000cfu were injected i.v. in 200μl 
of PBS with a 1ml insulin syringe (Beckton Dickinson, 041-BD-324827). Lymphocytic 
choriomeningitis virus (LCMV), strain Armstrong, was prepared as described in 281. 2x105pfu 
were injected i.p. in 200μl of PBS with 26G syringe needles (Terumo, 041-050101).  
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K.2.5 Adoptive T cell transfer 
CD8 T cells were harvested and CD3/CD28 Dynabeads were removed with an EasySep™ 
Magnet (Stem Cell, 18000). Cells were counted and washed 3 times in PBS. 0.2x106 cells were 
resuspended in 200μl of plain RPMI medium and injected in the mouse tail vein using 1ml 
insulin syringes.  
K.2.6 Fas-Fc treatment 
Human Fas linked to a human IgG1 Fc-tag (Adipogen, AG-40B-0082) or the human IgG1 Fc 
control (Adipogen, AG-35B-0007) were resuspended in PBS 1% BSA at the concentration of 
1mg/ml. 100μg were injected in mice i.v. with 1ml insulin syringes.  
K.2.7 Sample preparation, flow cytometry staining and acquisition 
Spleens were collected at indicated days post Listeria-OVA or LCMV infection and smashed on 
40μm cell strainers to obtain single cell suspensions. Red blood cells were lysed using a RBC 
Lysis Solution (Qiagen, 158902). Then, the cells were labelled with Zombie Yellow™ Fixable 
Viability Kit (Biolegend, 423103) to discriminate dead cells. HER2-specific CARs were labelled 
with HER2-Fc (Sino Biological, 10004-H02H-50) at 5μg/ml on ice for 20min and then washed 3 
times with facs buffer (PBS 2% FCS and 2.5mM EDTA). Next, cells were labelled with Brilliant 
Violet 421 anti-human IgG Fc Antibody (BioLegend, 409317) at 2μg/ml for 20min on ice and 
washed again 3 times. The CEA-specific CAR was instead stained with Fluorescein AffiniPure 
Goat Anti-Mouse IgG, F(ab')₂ (Jackson ImmunoResearch, 115-095-072) at 1μg/ml on ice for 
20min and then washed 3 times. 
After CAR staining, transduced cells were labelled with CD3e-Alexa Fluor 700 at 10μg/ml 
(BioLegend, 100215), CD8α-PE/TexasRed at 1/500 dilution (Thermo Fischer Scientific, 
MCD0817), CD45.1-APC/eFluor 780 at 2μg/ml (eBioScience, 47-0453-82), CD45.2-
PerCP/Cy5.5 at 2μg/ml (BioLegend, 109827), Fas-APC at 2μg/ml (BioLegend, 152603) and 
FasL-Biotin at 5μg/ml (BioLegend, 106603). Cells were then washed once and labelled with 
Streptavidin-PE/Cy7 at 0.4μg/ml (BioLegend, 405206). Finally, cells were washed again and 
stained with Annexin V-PE (BioLegend, 640907) according to the manufacturer protocol, and 
acquired on a BD LSR2 flow cytometer. 
K.2.8 In vitro cytokine release assay for CAR T cells 
0.2x106 OT-1 CAR T cells were plated in flat-bottom 96well plates with either 0.1x106 B16, 
B16-OVA or B16-HER2 tumor cells. 30min later, the Monensin and Brefeldin A-containing 
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reagents Golgi Stop and Golgi Plug (Beckton Dicksinon, 554724 and 555029) were added at 
the final concentration of 1:1000. Cells were further incubated for 4h prior to staining for flow 
cytometry. 
The cells were then labelled for viability and with HER2-Fc as described previously. They were 
also surface-labelled with the antibodies anti-human IgG Fc-FITC (BioLegend, 409309), CD3ε-
Alexa Fluor 700 at 10μg/ml (BioLegend, 100215) and CD8α-Brilliant Violet 650 at 0.5μg/ml 
(BioLegend, 100741). 
To stain for intracellular cytokines, cells were fixed and permeabilized (Biolegend, 420801) 
according to the manufacturer protocol, before being stained with the antibodies IFNγ-
PerCP/Cy5.5 at 0.5μg/ml (Biolegend, 505821) and TNFα-Pacific Blue at 1μg/ml (Biolegend, 
506318) diluted in permeabilization buffer (Biolegend, 421002) for 30min on ice. Cells were 
finally washed twice in permabilization buffer and resuspended in FACS buffer prior to 
acquisition. 
K.3 Results 
K.3.1 The CD3ζ endodomain mediates the CAR effector functions 
To address the effect of the presence of a CAR in CD8 T cells when engaged via their TCR, we 
cloned a CAR reactive to human HER2 using the 4D5 scFv277 antibody fragment fused to 
different TCR-associated signalling domains, respectively 4-1BB and CD3ζ (BBz), CD28 only 
(28), 4-1BB only (BB) and CD3ζ only (z). The CAR functionality requires the CD3ζ 
endodomain282, but we also tested CAR configuration with single domains other than CD3ζ to 
evaluate their influence on TCR signalling. In line with what is published, only the BBz and z 
HER2 CAR T cells secrete IFNγ and TNF-α when cocultured with B16 expressing HER2, whereas 
28 and BB CAR T cells were not activated (Figure 36).  
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Figure 36 - Chimeric antigen receptors encoding the CD3z endodomain mediate effector function in 
CD8 T cells. Untransduced or BBz, 28, BB or z CAR OT-1 T cells were cocultured with B16, B16-OVA or 
B16-HER2 for 4h and stained for (a) IFNγ and (b) TNF-α intracellularly. 
 
K.3.2 Several CAR configurations cause T cell deletion in vivo upon TCR engagement 
To address the effect of the presence of a CAR in T cells upon TCR engagement, we transduced 
OT-1 CD45.1 CD8 T cells with the BFP fluorescent protein as a control or with the HER2-specific 
CAR containing the signaling domains mentioned in the previous paragraph. These cells were 
transferred in CD45.2 recipient hosts, which were subsequently infected with Listeria-OVA to 
trigger transferred cells via their TCR but not via their CAR (Figure 37 A and B). As suspected 
from our preliminary results in vaccine setting, we observed that, while BFP-transduced OT-1 
T cells persisted well in mice 7 days post Listeria-OVA infection, CAR T cells with all CAR 
configurations has disappeared, as illustrated by the drop of CAR positive cells in the 
transferred OT-1 population (Figure 37 C). Next, we addressed the kinetic of the in vivo CAR T 
cell deletion upon TCR engagement and saw that initially CAR OT-1 T cells expanded well until 
day 5, while from day 6, they started to disappear and were totally gone at day 7 post infection 
(Figure 37 D). We investigated the cause underlying the death of CAR T cells upon TCR 
engagement in vivo and first checked the Fas/FasL pathway, which is a major mediator of T 
cell activation-induced cell death (AICD) 111. Interestingly, we found that CAR T cells 
upregulated Fas from day 6 and FasL at day 7 post infection, which was not the case for BFP-
transduced T cells (Figure 37 E). We also observed that these cells upregulated the early 
apoptosis marker phosphatidylserine, detected by Annexin V and about 20% of CAR-T cells 
were already apoptotic on day 6, as seen with the Vivid staining. In contrast, there was very 
low Annexin and/or Vivid staining in BFP-transduced cells (Figure 37 E), demonstrating that 
AICD is intrinsic to CAR-T cells. 
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Figure 37 - HER2-specific CAR T cells undergo apoptosis upon in vivo TCR activation (a) Schemes of 
HER2-CAR configurations. (b) CD45.1 OT-1 T cells transduced with BFP or HER2-CAR were transferred 
in CD45.2 C57BL/6 hosts, subsequently infected with Listeria-OVA (c) Frequencies of BFP or CAR T cells 
in transferred CD45.1 OT-1 population at day 7 post infection. (d) dot plots of frequencies of CAR–T 
cells at day 5,6 and 7 in the transferred OT-1 population. (e) Fas, FasL and Annexin V expression and 
Vivid viability staining in BFP or CAR-positive OT-1 T cells at day 6 and 7 post infection 
Since OT-1 T cells have a very high TCR avidity for the OVA epitope SIINFEKL expressed by 
Listeria-OVA, we tested whether CAR T cells would also be deleted when triggered via a 
decreased TCR signal, such as a self-derived tumor antigen. We therefore repeated the same 
experiment, using the Listeria -OVA  expressing the mutant epitope SIITFEKL T4, for which OT-
1 T cells have a 70x decreased avidity280. We confirmed the reduced avidity of OT-1 T cells for 
Listeria-T4 compared to the N4 strain, as seen by a significantly weaker OT-1 expansion in vivo 
(Figure 38 A). However, CAR T cells were similarly deleted in vivo whether the OT-1 TCR was 
triggered via the wild-type N4 and the low affinity T4 epitope (Figure 38 B).  
Collectively, these results show that CAR T cells are deleted in vivo upon TCR engagement 
whatever the CAR configuration and even upon low avidity TCR triggering. 
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Figure 38 – Low avidity TCR engagement renders a similar CAR T cell deletion in vivo than high avidity 
TCR. (a) Listeria-T4 expresses a low affinity OVA antigen and induces less proliferation of OT-1 T cells 
in vivo than Listeria-N4. OT-1 T cells were transferred in mice that were infected with either Listeria-
N4 or T4. The graph shows the percentage of OT-1 CD45.1 T cells in the total CD8 spleen population. 
(b) Percentage of BFP or HER2-BBz-positive OT-1 CD45.1 T cells at day 7 post infection with either 
Listeria-OVA N4 or T4. 
 
K.3.3 The deletion of CAR-T cells upon TCR triggering is independent of the TCR and CAR 
specificity 
To address whether the CAR T cell deletion that we observed was a general phenomenon, we 
transduced the HER2-BBz CAR in P14 CD8 cells specific for the LCMV gp33 epitope281. HER2-
CAR P14 cells were transferred in mice, which were then infected with LCMV Armstrong 
(Figure 39 A). In line with our previous results in OT-1 T cells, we observed that CAR P14 T cells 
were almost completely deleted at day 8 post LCMV infection (Figure 39 B and C). In contrast, 
control BFP-transduced P14 cells survived well the expansion phase. Additionally, we also 
observed Fas, FasL and Annexin V and Vivid upregulation in CAR T cells but not in BFP controls 
at day 7 post infection (Figure 39 D).  
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Figure 39 - CAR-P14 CD8 T cells also die upon in vivo TCR triggering (a) CD45.1 P14 CD8 T cells 
transduced with BFP or with HER2-BBz CAR were transferred in CD45.2 C57BL/6 hosts, subsequently 
infected with LCMV Armstrong. (b) Dot plots showing CAR-positive P14 T cells before transfer and at 
day 8 post infection. (c) BFP or CAR expression before transfer and in the spleen at day 8 post infection 
as % CD45.1 T cells. (d) Fas, FasL and Annexin V and/or viability staining in either BFP or CAR-positive 
transferred P14 T cells at day 6 and 7 post infection. 
Next, we tested whether CAR T cell apoptosis upon TCR engagement was independent of the 
CAR specificity. Therefore, we cloned a human CEA-specific CAR with the BBz endodomains, 
based on the MFE23 scFv278. OT-1 T cells were transduced and transferred in mice, which were 
infected with Listeria-OVA (Figure 40 A). Similarly to HER2-CAR, CEA-specific CAR T cells were 
also deleted in vivo upon TCR engagement (Figure 40 B and C). Accordingly, they also 
upregulated Fas, FasL and Annexin V and Vivid at day 6 and 7 post infection (Figure 40 D). 
Collectively, these results show that the inability of CAR T cells to persist in vivo upon TCR 
engagement is independently of the CAR and the TCR specificity. 
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Figure 40 - CEA-BBz OT-1 CD8 T cells also die when triggered in vivo via their TCR. (a) CD45.1 OT-1 CD8 
T cells transduced with BFP or CEA-BBz CAR were transferred in CD45.2 C57BL/6 hosts, subsequently 
infected with Listeria-OVA. (b) Dot plots showing CAR expression before transfer and at day 6 and 7 
post infection in the transferred OT-1 population. (c) Frequencies of BFP or CAR OT1 T cells before 
transfer and in the transferred CD45.1 OT-1 population at day 6 and 7 post infection. (d) Fas, FasL and 
Annexin V and/or viability staining in either BFP or CAR-positive transferred OT-1 T cells at day 6 and 7 
post infection. 
 
K.3.4 Fas blockade partially rescues CAR T cells from TCR-mediated AICD 
As we observed that CAR T cells upregulated Fas and FasL in vivo, which are key mediators of 
T cell contraction and AICD283, we asked whether Fas blockade would prevent the apoptosis 
of CAR OT-1 T cell upon challenge with Listeria-OVA. To this aim, we co-transduced OT-1 T 
cells with two retroviral particles, one expressing the BFP or the HER2-BBz CAR, and the 
second expressing ZsGreen fused to a miR-based shRNA either scrambled or specific for 
silencing Fas expression. In vitro validation of these constructions showed that all three miRs 
against Fas decreased the expression of Fas in CAR T cells, with however different efficiencies 
(Figure 41).  
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Figure 41 - Efficient Fas silencing of miR-based shRNA vectors against Fas. OT-1 T cells were co-
transduced with BFP or HER2-BBz CAR together with vectors encoding ZsGreen and miR-based shRNAs 
against Fas or a scrambled miR. The expression of Fas was assessed at day 5 post-transduction in cells 
transduced with the two vectors. 
Before in vivo transfer, CAR-ZsGreen co-transduced OT-1 T cells had to be sorted since only a 
small proportion of cells co-expressed both the CAR and the ZsGreen-miR-based shRNA which 
allowed transferring only 1500 cells. After cell transfer, mice were challenged with Listeria-
OVA (Figure 42 A). At day 7 post infection, we observed that OT-1 cells transduced with BFP 
and the scrambled miR retained higher levels of BFP expression among the transferred cell 
population, while as expected, most CAR T cells expressing the scrambled miR, had 
disappeared. Most importantly, about 40% of CAR T cells co-transduced with two independent 
miR-based shRNA against Fas were still detected (Figure 42 B and C). In a subsequent 
experiment, the efficiency of co-transduction of miRs and CARs has been improved, which 
allowed to transfer more CAR-miR T cells (30000) in host mice to test their in vivo rescue of 
CAR T cells via Fas blockade. Unfortunately, this new experiment did not allow confirming the 
rescue of TCR-activated CAR T cells, indicating that Fas might not be the only player.  
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Figure 42 - shRNA-mediated Fas blockade partially rescues TCR-activated CAR T cells. (a) CD45.1 OT-1 
CD8 T cells were co-transduced with BFP or HER2-BBz CAR together with vectors encoding ZsGreen 
and miR-based shRNAs against Fas or scramble. The cells were sorted for the expression of both the 
CAR and the miR and transferred in CD45.2 C57BL/6 hosts, followed by Listeria-OVA infection. (b) Dot 
plots showing the BFP or CAR expression at day 7 post Listeria-OVA infection in spleens of mice. (c) 
Frequencies of BFP or CAR T cells in the transferred CD45.1 OT-1 population at day 7 post infection.  
 
As a second attempt to block Fas-mediated AICD of CAR T cells, we treated mice with Fas-Fc 
post CAR-T cell transfer and Listeria-OVA infection. Briefly, OT-1 T cells transduced with BFP 
or HER2-BBz CAR were transferred in C57BL/6 hosts and infected with Listeria-OVA.  At days 
4 and 5 post infection, the mice received 100μg of Fas-Fc or a Fc tag alone as a control (Figure 
43 A).  As expected, CAR T cells were deleted in vivo at day 7 post infection in the control 
group, while we saw a partial rescue of CAR T cells in mice treated with Fas-Fc, which however 
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was not statistically significant (Figure 43 B). Unfortunately, the rescue of TCR-engaged CAR T 
cells upon Fas-Fc treatment could not be confirmed in repeat experiments. 
Collectively, these results show that the blockade of the Fas/FasL pathway is not consistently 
able to rescue the AICD of CAR T cells upon in vivo TCR engagement, which suggests that 
additional pathways may be involved in the deletion of TCR-triggered CAR T cells.  
 
 
 
Figure 43 - Fas-Fc-mediated Fas/FasL blockade partially rescues CAR T cells in vivo upon TCR 
engagement. (a) CD45.1 OT-1 CD8 T cells were transduced with BFP or with HER2-BBz CAR and 
transferred in CD45.2 C57BL/6 hosts, followed by Listeria-OVA infection. Mice were treated with 100μg 
of control-Fc or Fas-Fc at day 4 and 5. (b) Percentage of BFP or CAR expression before transfer and at 
day 7 post infection in the transferred population. 
 
K.4 Discussion 
Upon in vivo TCR engagement, we observed that CAR T cells initially expand normally like 
control cells. However, from day 6 post TCR stimulation, they undergo massive apoptosis in a 
Fas-dependent mechanism that resembles AICD. We showed that this phenomenon is 
independent of the TCR and CAR specificity, and also occurs upon low affinity TCR stimulation. 
These observations made in infectious models suggest that AICD of CAR T cell may also occur 
in tumor settings in which tumor antigens are generally recognized by low affinity TCRs. So far 
only indirect evidences from several studies have suggested that concomitant TCR and CAR 
engagement on the same T cell is not effective in terms of additive or synergistic antitumor 
effects. For instance, in the B16 melanoma tumor model, the group of Rosenberg could not 
show better antitumor effects of gp100-specific Pmel T cells when transduced with a VEGFR2 
CAR. Synergistic antitumor effects were only obtained when Pmel T cells were co-transferred 
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with  polyclonal T cells transduced with the VEGFR2-CAR284. The authors concluded that the 
different localization of the two antigens hindered a synergistic activation of CART-Pmel T 
cells. However, our observations suggest that TCR activation of Pmel-VEGFR2 CAR T cells by 
gp100-expressing tumor cells led to their AICD, independently of the CAR activation. 
Furthermore, a study tested the feasibility of transferring virus-specific (Epstein-Barr virus, 
cytomegalovirus, and adenoviruses) CAR CD8 T cells, hypothesizing that viral reactivation 
would enhance the expansion and persistence of CAR T cells. However, they found that viral 
activation induced only a modest expansion and antitumor activity of the infused CAR T 
cells285. Another indirect evidence of TCR-driven AICD of CAR T cells came from observations 
made in allogeneic hematopoietic stem-cell transplantation (alloHSCT) in leukemic paediatric 
patients286. Indeed, the severity of GvHD was much diminished when allogeneic HSCs were 
transduced with a CD19-CAR, as compared to untouched alloHSCs, suggesting that CAR T cells 
bearing a host-reactive TCR were deleted in the patients. Short time after, the same group has 
recapitulated their observations in mouse models, showing that CD28-containing CAR T cells 
expressing a host-reactive TCR progressively lost their effector functions and underwent 
clonal deletion287. However, they did not fully demonstrate the TCR-mediated apoptosis of 
CAR-T cells.  
Strikingly, we found that a single CD3z, CD28 or 4-1BB CAR domain was sufficient to mediate 
AICD of CAR T cells upon TCR engagement. This observation was particularly surprising  in the 
case of the 4-1BB-containing CAR since 4-1BB signalling is known to enhance the survival and 
delays exhaustion of effector T cells288. Along this line, the introduction of 4-1BB domain in 
CARs has conferred long persistence of CAR T cells in lymphoma patients289. However, in 
certain circumstances, 4-1BB can induce a Fas-mediated apoptosis290, which was also shown 
to happen in CAR T cells291. These authors reported that when a CAR is expressed under the 
control of the retroviral 5’ LTR promoter, it promotes a positive feedback loop in which the 
CAR triggering activates the NF-κB pathway, which promotes more CAR expression and 
overactivates the signalling through NF-κB. Finally, excessive NF-κB signalling leads to the 
upregulation of Fas and apoptosis, suggesting that CAR-related toxicity is dose-dependent. 
However, these mechanisms were not seen in clinical CAR therapy, because the CD19-CAR 
containing the 4-1BB domain292 was expressed in a sin lentiviral vector in which the LTR 
promoter is inactivated after genome insertion.  
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Until very recently, our observations of TCR-mediated CAR T cell AICD were not published. 
Unfortunately, while writing our manuscript, a publication from the group of Terry Fry 
reported that CD19-CAR CD8 T cells originating from female mice failed to reject murine 
lymphoma tumors when transferred in males in which the HY-specific TCR was activated 
resulting in CAR T cell death293. These results are very similar to what we obtained using 
infectious models. However, they did not show the involvement of Fas/FasL mediated 
apoptosis and instead showed caspase 3/7 activation. Interestingly, they reported that unlike 
CD8 CAR T cells, CD4 CAR T cells survived TCR activation and retained their antitumoral activity 
via CAR activation by the tumor. Our system using bacterial or viral infection resulted in a large 
initial expansion of CAR T cells upon TCR stimulation which allowed us to better visualize CAR-
T cell deletion and dissect the Fas/FasL-dependent mechanism.  In particular, we showed that 
blocking Fas/FasL pathway could partially rescue CAR T cells engaged via their TCR. However, 
the exclusive involvement of Fas/FasL could not be consistently confirmed, which suggests 
that in addition to Fas/FasL, other apoptotic pathways might be involved in the deletion of 
TCR-engaged CAR T cells. As a consequence, the need to block several apoptosis pathways 
would require heavy and costly interventions, which would not be applicable in a clinical 
setting. An alternative would be to use CD4 T cells as a CAR platform for combined TCR and 
CAR activation293. However, if this study showed that CD4 CAR T cells could exert an antitumor 
effect when triggered through their TCR, they ultimately did not survive, which would only 
allow a transient therapeutic effect. As an alternative to CD4 and CD8 T cells, iNKT cells have 
been shown to be a safe platform for CAR immunotherapy in a pre-clinical study294, and it 
would be interesting to evaluate whether CAR-iNKT cells would undergo AICD upon iNKT TCR 
activation. Finally, as published in the case of a 4-1BB containing CAR291, the dose of CAR 
expressed on the T cell surface was instrumental in mediating CAR T cell apoptosis upon TCR 
stimulation. Therefore, controlling the dose of CAR expressed in CD8 T cells may prevent their 
TCR-induced apoptosis. Indeed, our preliminary results (data not shown) indicate that a 
decreased CAR expression greatly improve the survival of TCR-triggered CAR T cells without 
significantly impeding the functionality of the CAR. Therefore, a tight control of the level of 
CAR expression may allow targeting solid tumors via both a tumor-specific TCR and a CAR. 
Finally, although it was shown that CAR signalling can also use the endogenous CD3 
complex295,  there are no report of excessive activation of the CAR leading to AICD. The best 
demonstration that this does not occur is the success of CAR-mediated immunotherapy, which 
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showed that CAR T cells may persist quite long in mice and cancer patients. Therefore, it is 
likely that the activation threshold required for AICD is not achieved upon CAR activation.  Our 
hypothesis is that high numbers of CAR molecules might be recruited at the TCR 
immunological synapse formed upon TCR activation. The accumulation of CAR co-stimulatory 
domains may greatly amplify the signal initiated by the TCR, thus accelerating exhaustion, and 
Fas/FasL pathway because of excessive signalling. To evaluate the recruitment of the CAR at 
the TCR synapse, we have developed a CAR, which is fused to the ZsGreen fluorescent protein. 
By confocal microscopy, we will investigate whether TCR engagement indeed recruits the CAR 
at the TCR synapse, hence increasing TCR signalling. More in depth biochemical studies will 
allow dissecting proximal and distal TCR signalling events in CAR T cells engaged via their TCR 
and evaluate whether the presence of the CAR co-stimulatory domains modifies the signalling 
events downstream of the TCR. 
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L General conclusion 
My first two projects aimed at improving therapeutic cancer vaccines by exploiting the 
adjuvant properties of iNKT cells. In the first project, we aimed at understanding how Th1 and 
Th2 αGalCer analogs induce or not iNKT cell anergy, in order to design new analogs which 
would allow vaccinating cancer patients repeatedly. Unfortunately, we found that Th2 analogs 
which only weakly induce iNKT cell anergy, also confer iNKT cells with a poor adjuvant activity 
on DC maturation. In this context, several groups have tried to optimize the structure of 
αGalCer to improve its adjuvant properties. For instance, the analog 7DW8-5 induced a 
superior priming of CD8 T cells than αGalCer239, and its addition to an Adenovirus-based 
vaccine against malaria strongly enhanced the CD8 T cell response in primates296. 
Interestingly, our results on this glycolipid also revealed that it induces less iNKT cell anergy 
than αGalCer, although its structure is rather apolar. These results indicate that it is possible 
for an αGalCer analog to combine a strong Th1 phenotype with a reduced anergy induction. 
In contrast, c-GalCer, which is a potent Th1 agonist241, strongly induces iNKT cell anergy. 
Altogether, the chemical and cellular parameters which control the adjuvant activity versus 
anergy induction of iNKT cells are not fully understood and it is not clear yet to which extent 
these processes can be dissociated. 
In the second project, we confirmed the superiority of therapeutic cancer vaccines based on 
the intravenous transfer of ex vivo DCs loaded with αGalCer and peptide, as compared to 
subcutaneous peptide and poly(I:C) formulation. For instance, DCs loaded with αGalCer and 
the TAA NY-ESO-1 were recently challenged in a phase I clinical trial, which demonstrated their 
potency to induce a CD4 and CD8 T cell response against the NY-ESO-1 antigen in melanoma 
cancer patients. These encouraging results led to the setup of a phase II trial, which is now 
recruiting patients. Importantly, we showed that the antitumor response mediated by the 
adjuvant activity of iNKT cells is strongly improved by the addition of PD1 checkpoint blockade, 
which to our knowledge was not yet shown. The combined vaccination and anti-PD1 
treatment improved both the priming of T cells and their effector functions inside the tumor 
These results are promising since DC vaccines are yet suboptimal297,298, and only one modality, 
Sipuleucel-T299, has reached the market so far. As seen already in the clinic, we found that the 
efficacy of PD1 checkpoint blockade largely depends on the immunogenicity of the tumor and 
its degree of T cell infiltration. However, the simultaneous DC loading with αGalCer and 
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peptide antigen could enhance therapeutic response of poorly immunogenic tumors. A 
promising alternative will be to pulse DCs with oxidized tumor lysates as tested clinical trials 
in ovarian cancer patients182,257. The combined loading of αGalCer with tumor lysates might 
further enhance T cell response against poorly immunogenic tumors.  
The third project has demonstrated that TCR engagement in CAR CD8 T cells leads to Fas-
mediated AICD, which precludes the combined TCR and CAR activation, as an improved 
strategy of CAR therapy against solid tumors. However, several alternatives may allow the 
rescue of CAR T cells upon TCR triggering. Interestingly, we showed that Fas/FasL blockade 
could not consistently rescue CAR T cells when activated through their TCR, which suggests 
that several pathways in addition to Fas/FasL are involved in the deletion of TCR-engaged CAR 
T cells. Therefore, blocking more than one pathway in CAR T cells would require heavy 
interventions that may not be applicable in a clinical condition. Alternatively, it would be 
interesting to combine CAR and TCR activation in CD4 T cells, which were shown by Fry et al.293 
to be less prone to TCR-mediated apoptosis. Moreover, the number of CAR molecules 
expressed in a given T cell might greatly influence the level of activation of its TCR, and a tight 
control of the dose of CAR expression may limit the TCR-induced AICD of CAR T cells as shown 
previously with regard to 4-1BB-containing CARs291.  Indeed, our preliminary data show that a 
low CAR expression prevents the apoptosis of TCR-triggered CAR T cells without impeding the 
function of the CAR. Thus, a controlled CAR expression in tumor-specific T cells may allow 
TCR/CAR combined activation against tumors expressing both antigens. Additionally, iNKT 
cells were shown by others as a safe CAR platform294, and it would be interesting to test 
whether iNKT TCR engagement in the presence of a CAR would or would not lead to apoptosis.  
Finally, a better understanding as how the TCR machinery copes with the presence of CAR co-
stimulatory domains may certainly help finding ways to avoid CAR T cell AICD upon TCR 
engagement. 
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